
http://eprints.gla.ac.uk/53645/

Deposited on: 4 July 2011
Mechanisms of termination and prevention of atrial fibrillation by drug therapy

Workman AJ, Smith GL, Rankin AC

Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA

Corresponding author: Dr Antony J Workman, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom. Tel.: +44 (0)141 330 3451. Fax.: +44(0)141 330 6997. Email: Antony.Workman@glasgow.ac.uk

Abstract
Atrial fibrillation (AF) is a disorder of the rhythm of electrical activation of the cardiac atria. It is the most common cardiac arrhythmia, has multiple aetiologies, and increases the risk of death from stroke. Pharmacological therapy is the mainstay of treatment for AF, but currently available anti-arrhythmic drugs have limited efficacy and safety. An improved understanding of how anti-arrhythmic drugs affect the electrophysiological mechanisms of AF initiation and maintenance, in the setting of the different cardiac diseases that predispose to AF, is therefore required. A variety of animal models of AF has been developed, to represent and control the pathophysiological causes and risk factors of AF, and to permit the measurement of detailed and invasive parameters relating to the associated electrophysiological mechanisms of AF. The purpose of this review is to examine, consolidate and compare available relevant data on in-vivo electrophysiological mechanisms of AF suppression by currently approved and investigational anti-arrhythmic drugs in such models. These include the Vaughan Williams class I-IV drugs, namely Na\(^+\) channel blockers, β-adrenoceptor antagonists, action potential prolonging drugs, and Ca\(^{2+}\) channel blockers; the “upstream therapies”, e.g., angiotensin converting enzyme inhibitors, statins and fish oils; and a variety of investigational drugs such as “atrial-selective” multiple ion channel blockers, gap junction-enhancers, and intracellular Ca\(^{2+}\)-handling modulators. It is hoped that this will help to clarify the main electrophysiological mechanisms of action of different and related drug types in different disease settings, and the likely clinical significance and potential future exploitation of such mechanisms.

Keywords
1) Atrial fibrillation
2) Cardiac arrhythmia mechanisms: reentry, afterdepolarisations
3) In-vivo animal models
4) Pathological electrical remodelling
5) Pharmacological treatment
6) Anti-arrhythmic drug mechanisms

Contents
1. Introduction
2. Electrophysiological mechanisms of AF and implications for drug actions
3. In-vivo models of AF used to investigate mechanisms of anti-arrhythmic drugs
4. Drug types for AF termination and prevention: conventional anti-arrhythmics; upstream therapy; investigational
5. Class I drugs (Na\(^+\) channel blockers): in-vivo electrophysiological mechanisms of AF termination
6. Class II drugs (β-blockers): electrophysiological mechanisms of AF suppression in-vivo
7. Class III drugs (APD-prolonging): in-vivo electrophysiological mechanisms of AF termination and prevention
8. Class IV drugs (Ca\(^{2+}\) channel blockers): electrophysiological effects in in-vivo models of AF
9. Upstream therapies and other clinically available agents: in-vivo mechanisms
10. Investigational anti-arrhythmic drugs: in-vivo electrophysiological mechanisms of AF termination and prevention
11. Concluding remarks and future directions

Abbreviations
ACE: angiotensin-converting enzyme; AF: atrial fibrillation; AFCL: AF cycle length; APD: action potential duration; DAD: delayed afterdepolarisation; EAD: early afterdepolarisation; ERP: effective refractory period; I\(_{\text{CaL}}\): L-type Ca\(^{2+}\) current; I\(_{\text{CaT}}\): T-type Ca\(^{2+}\) current; I\(_{f}\): funny current; I\(_{\text{K1}}\): inward rectifier K\(^+\) current; I\(_{\text{KAC}}\): acetylcholine-activated K\(^+\) current; I\(_{\text{Ks}}\): rapid delayed rectifier K\(^+\) current; I\(_{\text{Kr}}\): slow delayed rectifier K\(^+\) current; I\(_{\text{Kur}}\): ultra-rapid delayed rectifier K\(^+\) current; I\(_{\text{Na}}\): Na\(^+\) current; I\(_{\text{Na/Ca}}\): Na\(^+\)-Ca\(^{2+}\) exchanger current; I\(_{\text{Na/H}}\): Na\(^+\)-H\(^+\) exchanger current; I\(_{\text{NaL}}\): late I\(_{\text{Na}}\); I\(_{\text{SKCa}}\): small conductance Ca\(^{2+}\)-activated K\(^+\) current; I\(_{\text{TO}}\): transient outward K\(^+\) current.
1. Introduction

Atrial fibrillation (AF) is a disturbance of the normally rhythmical beating of the cardiac atria, characterised by rapid (e.g., 400-600 beats/minute), irregular electrical and mechanical activation of the atrial muscle. It is the most common cardiac arrhythmia encountered in clinical practice, and has multiple causes, such as coronary artery disease, heart failure, valve disease and hypertension. Patients with AF have an increased risk of death from stroke, due to embolisation of atrial thrombi which form because the rapid and irregular activation causes uncoordinated atrial contraction and hence disturbed and reduced atrial blood flow. AF can be treated with electrical cardioversion, tissue ablation, and pharmacological therapy; the latter being the mainstay, particularly in the expanding elderly population. However, currently available anti-arrhythmic drugs are only moderately effective in preventing or terminating AF or maintaining sinus rhythm after it is restored, and may also exert adverse effects such as ventricular pro-arrhythmia, organ toxicity, or both (Camm et al., 2010).

Therefore, there is a major unmet need to develop more effective and safe drugs to control the atrial rhythm in patients with AF. This necessitates a drive towards an improved understanding of the various and complex mechanisms by which anti-arrhythmic drugs affect the electrophysiological mechanisms of AF initiation and maintenance, in the setting of the different cardiac pathologies underlying the arrhythmia. An essential part of this is to study patients in the clinic, and their isolated atrial tissues and cells, where possible. However, such studies are usually limited by confounding influences of multiple variables such as patient age, sex, disease history and drug treatments, and also by the difficulty or inability to measure required electrophysiological parameters from human hearts in-vivo. For this reason, various in-vivo animal models of AF have been developed to permit the necessary control over physiological and pathophysiological variables in different disease states in isolation, and also the continuous measurement of detailed and invasive parameters relating to the associated electrophysiological mechanisms of AF.

The purpose of this review is to examine, consolidate and compare available relevant data on in-vivo electrophysiological mechanisms of AF suppression by currently and previously approved, and investigational, anti-arrhythmic drugs in such models. The focus, therefore, is on studies of atrium in in-vivo animal models. However, clinical electrophysiological data are utilised where available, and relevant in-vitro studies, including of ventricle, are incorporated where in-vivo data are lacking. For evaluation of clinical trials of current pharmacological and non-pharmacological interventions, the reader is directed to current European (Camm et al., 2010) and American (Fuster et al., 2006; Wann et al., 2011) guidelines for the management of patients with AF. Details of molecular mechanisms of many of the anti-arrhythmic drugs are found in (Ravens, 2010). It is hoped that this review will help to clarify the main in-vivo electrophysiological mechanisms of action of different drug types in different disease settings, and the likely clinical significance and potential future exploitation of such mechanisms.

2. Electrophysiological mechanisms of AF and implications for drug actions

A variety of electrophysiological mechanisms of arrhythmia, reentrant and non-reentrant, likely initiates and maintains AF (Figure 1). Which of these mechanisms predominate in patients and animal models of AF depends partly on the underlying myocardial disease, because of disease-specific patterns of atrial electrical and structural changes, including long term remodelling (Workman et al., 2008). The clinical spectrum of AF ranges from paroxysmal (self-terminating episodes) to persistent (lasting >7 days) to permanent (pharmacologically and electrically inconvertible). The majority of atrial premature beats that initiate AF in patients originate from focal ectopic activity in or near the pulmonary veins, which may be either micro-reentrant or non-reentrant (Haissaguerre et al., 1998). Subsequent progression to persistent or permanent AF likely reflects the time-course and types of the atrial remodelling which, by their effects on the arrhythmia mechanisms, are expected to influence also the efficacy of pharmacological therapy.

2.1. Reentry

Reentry is rapid circuitous myocardial activation by an action potential wavefront as it continuously circulates a region of conduction block, re-exciting previously refractory tissue. This region of conduction block may be functional, i.e., a patch of refractory myocardial tissue, or anatomical/structural, e.g., a coronary vessel or a myocardial lesion; giving rise to functional and anatomical/structural reentry, respectively. The two main competing, but related, concepts of functional reentry are “leading circle reentry” and “spiral wave reentry”. For a comprehensive historical perspective on the development of the theoretical and experimental bases for our understanding of the different mechanisms of reentry, see (Jalife, 2010), which includes the major contributions from the laboratories of Moe, Allessie, Jalife, Haissaguerre, and others.

2.1.1. Leading circle reentry

In leading circle reentry, propagation is at the leading tip of a circuit located around a circle of critical dimensions, with wavelets emanating from that circle constantly maintaining the central core in a refractory state. The circumference of the circle, i.e., the minimum wavelength of the circuit, λ, is the effective refractory period (ERP) x conduction velocity (θ)
Furthermore, drugs which reduce I_{Na} conduction velocity and wavelength, particularly in a spatially heterogeneous manner, could promote reentrant AF. and on the degree of any intercellular fibrosis. Therefore, myocardial diseases which reduce such coupling, and thus repolarisation is complete or nearly complete (Wit & Boyden, 2007). EADs are favoured by an increase in the APD outward, hyperpolarising, currents such as the delayed rectifiers. Triggered activity is premature firing due to effects. Furthermore, an increase in the spatial or temporal heterogeneity of electrical activity, e.g., resulting from localised interstitial fibrosis, or discordant alternans of the action potential duration (APD), will increase the likelihood of unidirectional conduction block and reentry (Figure 1). The ERP is determined by membrane excitability, i.e., the availability of Na⁺ channels to open and pass inward Na⁺ current (I_{Na}) and thus initiate the upstroke of an action potential. I_{Na} is voltage-dependent, and because it becomes available to open only after near full repolarisation of the preceding action potential, the ERP is largely determined by the APD at terminal repolarisation. In turn, this is determined by the magnitude and time course of repolarising K⁺ currents such as the ultra-rapid (I_{Kur}), rapid (I_{Kr}), and slow (I_{Ks}) delayed rectifier K⁺ currents, and inward rectifier K⁺ currents such as I_{K1} and the acetylcholine-activated K⁺ current (I_{KACCh}). Therefore, drugs which inhibit these K⁺ currents could inhibit or extinguish reentrant AF, by prolonging APD and ERP and thus increasing wavelength. For further detail on how inhibition of human atrial repolarising ion currents could affect the morphology and duration of the action potential, see illustrations in (Workman, 2010) and (Ravens, 2010). Myocardial conduction velocity is determined partly by the maximum rate of rise of the action potential upstroke, which is dependent on membrane excitability and I_{Na} magnitude. However, conduction velocity also depends largely on the degree of intercellular coupling, which depends on intercellular communication via gap junctions at the intercalated discs, and on the degree of any intercellular fibrosis. Therefore, myocardial diseases which reduce such coupling, and thus conduction velocity and wavelength, particularly in a spatially heterogeneous manner, could promote reentrant AF. Furthermore, drugs which reduce I_{Na} sufficiently to reduce conduction velocity should also be expected, by leading circle reentry, to promote reentrant AF.

### 2.1.2. Anatomical/structural reentry

For anatomical/structural reentry to occur, as with leading circle reentry, the wavelength of the reentrant circuit must be shorter than the available conduction pathlength. The conduction path is fixed, determined by the size of the anatomical/structural obstacle or feature and may be large, leaving a large excitable gap and producing regular and relatively slow-rate reentry. For example, in the most common form of the supraventricular arrhythmia, atrial flutter, in which reentry rate is typically ~300 beats/minute, the reentry circuit passes through a muscle isthmus adjacent to the tricuspid valve, the neighboring posterior right atrium, and the ostium of the coronary sinus (Gami et al., 2010). Anatomical/structural reentry may also be involved in both the generation and maintenance of AF.

### 2.1.3. Spiral wave reentry

In spiral wave reentry, curved activation wavefronts propagate outwards into excitable tissue in a spiral fashion, with their tips, which have the highest curvature, revolving around a central core (Figure 1). As with leading circle reentry, changes in ERP will tend to affect core size, but can also cause complex changes in wave tip trajectory that may lead to tip meandering and wave break up. Furthermore, the degree of curvature of the wave tip also affects core size. High curvature produces a small core, short excitable gaps and a high reentry rate, which manifests as a short AF cycle length (AFCL), the minimum interval between successive atrial electrogram deflections. The degree of curvature is determined by the strength of the wavefront “source” (I_{Na}) or “sink” (electrotonic influence of the resting cells). A reduction in I_{Na} reduces curvature, increasing core size and decreasing reentry rate, even when there is a full excitable gap, ultimately potentially blocking reentry. Conversely, reentry rate may increase when I_{K1} is increased, by an increase in electrotonic effects. Furthermore, an increase in ERP, e.g., by decreasing delayed rectifier K⁺ current, may cause a transition from a stable circular to a meandering spiral wave. Therefore, the effects of drugs which block, for example, Na⁺ or K⁺ channels, on reentrant mechanisms of AF are expected to differ according to which of the two models of reentry are considered to operate (Comtois et al., 2005).

### 2.2. Non-reentry

Non-reentrant mechanisms of arrhythmia include abnormal automaticity and triggered activity (Figure 1). Abnormal automaticity is the premature firing of action potentials due to accelerated diastolic depolarisation. This is favoured by an increase in diastolic inward, depolarising, ion currents such as the funny current (I_f), and also by a decrease in outward, hyperpolarising, currents such as the delayed rectifiers. Triggered activity is premature firing due to afterdepolarisations, which are either early (EAD), occurring during repolarisation, or delayed (DAD) until repolarisation is complete or nearly complete (Wit & Boyden, 2007). EADs are favoured by an increase in the APD that permits reactivation of I_{CaL}, or by abnormalities in I_{Na} activation or inactivation. DADs (and also abnormal automaticity) are favoured by excessive increases in intracellular Ca²⁺ concentration. For example, β-adrenoceptor stimulation may increase the L-type Ca²⁺ current (I_{CaL}) and the sarcoplasmic reticular Ca²⁺ content sufficiently to cause propagating waves of Ca²⁺-induced Ca²⁺ release via the ryanodine receptors (Eisner et al., 2009). This in turn may...
cause DADs by activating a transient inward, depolarising, current carried by the Na\(^+\)-Ca\(^{2+}\) exchanger (I_{Na,Ca}) as each extruded Ca\(^{2+}\) is exchanged with 3 Na\(^+\). Therefore, drugs which inhibit ion currents such as I_t and I_{CaL}, or which antagonise β-adrenoceptors or suppress intracellular Ca\(^{2+}\) elevation, might be expected, in theory, to suppress non-reentrant mechanisms of AF.

[insert Figure 1]

3. **In-vivo models of AF used to investigate mechanisms of anti-arrhythmic drugs**

3.1. **In-vivo model-types and clinical counterparts**

A wide variety of in-vivo models of AF has been used to study electrophysiological mechanisms of the development of this arrhythmia and, in most cases, to investigate the effects of drugs on such mechanisms. The interventions used generally mimic, as far as possible, clinical risk factors for AF (both established and potential). The major risk factors for AF are heart failure and a variety of associated or causative chronic myocardial diseases such as coronary artery disease, myocardial infarction, hypertrophy, hypertension, atrial dilation and valve disease (Camm et al., 2010). Each may cause chronic adaptational changes, “remodelling”, of atrial structure and function, and also neurohumoral imbalance. This may result in an “arrhythmogenic substrate”, an atrial myocardium predisposed to reentrant, or non-reentrant, electrical activity (Figure 1). Furthermore, once AF occurs, a persistence of the rapid atrial activation also causes atrial remodelling that promotes AF (Wijffels et al., 1995). Therefore, most of the animal models feature chronic interventions, of at least 2 week’s duration. A predisposition to AF also may result from acute risk factors and stimuli (in the presence or absence of remodelling) such as elevated adrenergic and/or cholinergic stimulation, acute atrial dilation and stretch, and cardiac surgery. Therefore, acute models of AF have also been studied. All these chronic and acute models of AF, with the main atrial electrophysiological changes produced in each, are given in Table 1, along with comparative clinical data where available. Each intervention either produced spontaneous AF, eased the induction of AF by electrical stimuli (increased its “vulnerability”) or increased its duration before spontaneous reversion to sinus rhythm.

[insert Table 1]

3.1.1. **Heart failure and myocardial infarction models of AF**

The most extensively studied heart failure model of AF is the dog chronic (2-6 week) ventricular tachypacing model, exemplified by studies from the Nattel laboratory (see (Li et al., 1999) and Table 1). This model reproduced the major haemodynamic, structural and biochemical changes which accompany human heart failure, e.g., left ventricular systolic dysfunction and hypertrophy, increased atrial pressure, dilation and interstitial fibrosis, atrial hypocontraction, and catecholamine elevation (Moe et al., 1989; Li et al., 1999; Stambler et al., 2003; Cha et al., 2004). It also remodelled atrial ion currents, decreasing transient outward K\(^+\) current (I_{to}), I_{CaL} and I_KS and increasing I_{Na,CA} (Cha et al., 2004), but did not consistently change ERP, conduction velocity or AFCL in-vivo (Table 1). The fibrosis caused localised conduction-slowing and increased dispersion (spatial heterogeneity) of conduction velocity (Shinagawa et al., 2002c) which could promote reentry, especially in a dilated atrium, which would increase the available conduction pathlength (Figure 1). However, this model of heart failure could also produce non-reentrant atrial activity, since “spontaneous Ca\(^{2+}\) transient events” which may cause DADs were observed in-vitro (Yeh et al., 2008). Furthermore, localised, stable, high frequency foci were produced in right atrium and within or near the pulmonary veins (Fenelon et al., 2003; Ryu et al., 2005). While those could be micro-reentrant, the finding that the 1st beat and mean cycle length of atrial tachycardia were directly related to the cycle length of the burst of stimuli that provoked the atrial tachycardia suggests that a triggered mechanism is more likely (Stambler et al., 2003).

Heart failure in patients was associated with a moderate increase or no change in atrial ERP in-vivo (Sanders et al., 2003). However, a recent study in our laboratory showed that left ventricular systolic dysfunction in patients was independently associated with a reduction in the ERP of atrial cells in-vitro, with decreasing left ventricular ejection fraction correlating with ERP-shortening (Workman et al., 2009). Such ERP-decrease could promote reentry by decreasing wavelength. In support, evidence is emerging that a relatively longer duration of heart failure in dogs (16 weeks ventricular tachypacing) may also decrease atrial ERP, both in-vivo (Table 1) and in-vitro (Sridhar et al., 2009). The type of AF-promoting atrial electrical remodelling may depend in part, therefore, on the duration of heart failure, with short duration perhaps favouring non-reentry, and long duration perhaps favouring reentry (Rankin & Workman, 2009). However, the arrhythmia mechanism will also be influenced substantially by the degree of atrial structural remodelling, which is also time- as well as aetiology-dependent. There are few studies of atrial remodelling by ventricular myocardial infarction, a major cause of heart failure. In dogs, coronary artery ligation for 8 weeks had no effect on atrial ERP in-vivo (Table 1), although it caused APD alternans, an increased APD dispersion, a degeneration of activation into multiple wavelets, and a decreased conduction velocity. In rats, chronic myocardial infarction caused atrial fibrosis (Boixel et al., 2003). Preliminary data from our laboratory suggest that chronic myocardial infarction in rabbits causes atrial cellular hypertrophy and defects in atrial excitation-contraction coupling in the presence of β-adrenergic stimulation (Kettlewell et al., 2010).
3.1.2. Acute and chronic atrial dilation models of AF

Acute and chronic atrial dilation has been investigated with a variety of species and interventions. Surgical disruption of tricuspid or mitral valves (Boyden & Hoffman, 1981; Verheule et al., 2003) caused chronic atrial volume overload from valvular regurgitation. Chronic atrial dilation was also produced by atrioventricular node ablation (Greiser et al., 2009) or with an arterio-venous shunt (Remes et al., 2008). Each model produced broadly similar atrial electrophysiological changes, so are grouped in Table 1 as “chronic atrial dilation”. The promotion of AF was accompanied by either increased or unchanged ERP, decreased or unchanged conduction velocity, and unchanged AFCL, from which it was suggested that the AF was not caused by wavelength-decrease in this model (Verheule et al., 2003). However, an increase in the available conduction pathlength from the dilation, perhaps coupled with fibrosis, inflammation and increased conduction velocity-dispersion (Verheule et al., 2003) could predispose to reentry, and atrial activation mapping demonstrated reentry in-vitro in the rabbit shunt model (Hirose et al., 2005). In patients, it is difficult to isolate effects of chronic atrial dilation from pathological covariables. Nevertheless, atrial enlargement was associated with an increase in atrial ERP (Chen et al., 1998), in line with some of the animal studies. Acute atrial dilation and stretch, precluding remodelling effects, were studied in-vivo, including in patients, using balloon catheters, volume-expanding solutions, or simultaneous-atrioventricular-pacing. Each intervention increased AF vulnerability, but effects on ERP were inconsistent (Table 1), including within species. However, ERP-dispersion was increased (Satoh & Zipes, 1996) and conduction velocity was decreased (Solti et al., 1989), both favouring reentry. In-vivo studies of hypertension-induced AF, e.g., following renal artery clamping are few (Table 1), and effects on ERP were variable, but a decreased conduction velocity and wavelength, and increased conduction velocity-dispersion (Lau et al., 2000), particularly in enlarged (Kistler et al., 2006) or fibrosed (Kistler et al., 2006; Choisy et al., 2007) atria, could promote reentrant AF.

3.1.3. Autonomic-imbalance models of AF

Variations in autonomic tone profoundly influence the occurrence of AF, with increased cholinergic (vagal) or adrenergic (sympathetic) activity promoting AF. Cholinergic AF has been studied in-vivo by stimulating vagal nerves (Wang et al., 1993; Hayashi et al., 1998; Fedorov et al., 2000; Hashimoto et al., 2006; Sarrazin et al., 2007), by using α-chloralose anaesthesia (David et al., 1990) or by delivering acetylcholine, carbachol or methylcholine intraatrially (Rensma et al., 1988), intrapericardially (Kumar et al., 2009), intravenously (Verceck et al., 2001; Everett et al., 2006), intraperitoneally (Kovoor et al., 2001) or topically (Niu et al., 2009). This invariably produced AF spontaneously or increased its vulnerability. Atrial ERP and wavelength were consistently and markedly decreased, with no effect on conduction velocity (Table 1). The mechanism of ERP-shortening is acceleration of terminal repolarisation as a result of cholinergic activation of I_{K\text{ACh}}. It is noteworthy that activation of agonist-independent (constitutively active) I_{K\text{ACh}} (Dobrev et al., 2005) is considered to be a major determinant of atrial ERP-shortening associated with chronic AF in patients (see section 3.1.7). In dogs, a high dominant frequency of activation during cholinergic AF, measured by spectral analysis, indicated multiple high frequency zones (Everett et al., 2006). Focal, rapidly-firing, rotor-like electrograms were also recorded (Niu et al., 2009). An in-vitro study showed that the increase in atrial dominant frequency by acetylcholine likely depended both on acetylcholine concentration and I_{K\text{ACh}} magnitude (Sarmast et al., 2003). The arrhythmia mechanism has been mapped in-vivo in dogs, and macro-reentry resulting from unidirectional conduction block was demonstrated (Derakhch et al., 2001). In patients, promotion of atrial reentry by cholinergic stimulation was suggested by effects of adenosine (which activates the same K⁺ channels as acetylcholine) to increase atrial dominant frequency; supported by mathematical modelling of effects of increasing I_{K\text{ACh}} on reentrant drivers (Aitenza et al., 2006). Adrenergic stimulation, with intravenous isoprenaline, was studied in several species including human. AF vulnerability or incidence were consistently increased, but effects on other electrophysiological parameters were variable (Table 1). For example, in patients, isoprenaline caused a marked increase in conduction velocity and a small decrease in ERP, thus increasing wavelength (Shimizu et al., 1994), whereas in dogs, isoprenaline had no effect on wavelength (Rensma et al., 1988). Furthermore, adrenaline prolonged ERP in rabbit atra in-vitro (Smeets et al., 1986), whilst isoprenaline had no effect on ERP in human atrial isolated cells (Redpath et al., 2006). It is unclear whether adrenergic stimulation causes AF by reentry in-vivo, although isoprenaline sustained reentry in atrial/pulmonary vein tissues in-vitro (Arora et al., 2003). Non-reentrant mechanisms are likely prominent, either from DADs or abnormal automaticity resulting from increased intracellular Ca²⁺ and consequent I_{Na\text{Caa}} primarily from stimulation of I_{CaL} and A-kinase mediated phosphorylation of phospholamban (Workman, 2010). Simultaneous cholinergic/adrenergic discharges are common triggers of paroxysmal atrial tachycardia and paroxysmal AF, and the stimulation of ganglionic plexi (sites rich in cholinergic and adrenergic neurons) at the pulmonary vein-left atrial junction can facilitate the onset of these arrhythmias. The mechanism may involve the formation of afterdepolarisations as a result of intracellular Ca²⁺-elevation in the presence of APD-shortening (Chou & Chen, 2009). In a dog in-vivo model of AF (“local nerve-stimulation” in Table 1), high frequency electrical stimulation of the atrial surfaces might induce AF as a result of a simultaneous increase in cholinergic and adrenergic nerve activity.
3.1.4. Models of post-operative AF and atrial ischaemia

AF is common after cardiac surgery, probably from multiple mechanisms such as autonomic imbalance, acute ischaemia, mechanical irritation, and pericarditis. Old age is a strong predictor of post-cardiac surgery AF, likely by conduction disturbances arising from increased atrial fibrosis, whereas pre-surgery atrial cellular electrophysiology probably is not (Workman et al., 2006). The sterile pericarditis model is an experimental counterpart to the patient post-cardiac surgery. It promotes AF, associated with changed atrial ERP and conduction velocity (Table 1). The primary arrhythmia mechanism is probably reentry (Matsumoto et al., 2010), consistent with reduced wavelength and with functional lines of block due to conduction velocity-dispersion from altered gap junction distribution and/or fibrosis (Ryu et al., 2007). Acute atrial ischaemia was studied independently, by right coronary ligation in dogs. This invariably increased AF duration, and while effects on ERP were highly variable, conduction velocity always decreased (Table 1). Ischaemia also increased atrial conduction velocity-dispersion (Sakabe et al., 2008), impaired conduction between normally- and hypoperfused atrial myocardium (Shirohsita-Takeshita et al., 2007b), or impaired ERP rate-adaptation; the ability of increasing rate to shorten ERP (Jayachandran et al., 2000). These effects could promote reentry, but triggered activity from increased atrial intracellular Ca\(^{2+}\), e.g., from glycolytic inhibition (Ono et al., 2007), or from a rapid transient increase in APD, as shown in ventricle (Workman et al., 2000), should not be excluded. Chronic atrial infarction has also been studied, in dogs, by ligating the right intermediate atrial artery for 8 days (Table 1). This caused stable reentry circuits in the infarction border zone and increased the duration of burst pacing-induced AF, associated with increased conduction velocity-heterogeneity and fibrosis, and altered intracellular Ca\(^{2+}\)-handling (Nishida et al., 2011).

3.1.5. Transgenic mouse and other relevant models of AF

Other in-vivo animal models of AF, most of which have been used to investigate anti-arrhythmic mechanisms of drugs, include hypercapnia or transient asphyxia (relating to AF associated with sleep disordered breathing), hypoglycaemia, atrial mechanical injury (relating to conduction block from, e.g., scar, fibrosis), aconitine (“window” I\(Ca\_a\) agonist)-induced triggered AF and a variety of transgenic mouse models (Table 1). Persistent conduction-slowing followed hypercapnoea-reversal in sheep, and hypoglycaemia decreased ERP in dogs. The atrial injury models reliably produce reentry, e.g., around Y-shaped lesions (Jahil et al., 1997), and have been used extensively for pharmacological study. Genetically engineered over-expression of the ion channel protein Kir2.1 increased I\(K1\) and decreased atrial ERP (Li et al., 2004); electrical changes commonly associated with human chronic AF (Workman et al., 2008). Under-expression (Zhang et al., 2005) or knockout (Mancarella et al., 2008) of Cav1.3 or \(\alpha_{1D}\) to decrease I\(Ca\al\), increased AF vulnerability without changing ERP. KCNE1-knockout, which paradoxically increased I\(KS\), increased AF incidence (Temple et al., 2005). Connexin40-knockout, to decrease gap junction-coupling, decreased conduction velocity; and Rac1 over-expression, to produce reactive \(O_2^*\) species and atrial fibrosis, also decreased conduction velocity (Reil et al., 2010). Altered ryanodine receptor function due to mutations (Chelu et al., 2009), or to knockout of an associated regulatory protein, FKBP12.6 (Sood et al., 2008) promoted AF, likely by enhancing spontaneous diastolic sarcoplasmatic reticular Ca\(^{2+}\) release.

3.1.6. AF causes AF by electrical remodelling: chronic rapid atrial rate models

AF normally occurs initially in short, self-terminating bouts, paroxysms, which may then become progressively longer. A persistence of the rapid atrial activation for several hours is sufficient in itself (i.e., in the absence of initial underlying pathology) to cause substantial AF-promoting atrial electrical remodelling. This was demonstrated first in goats, by the Allessie group: after 24 hr of burst pacing-induced AF, atrial ERP and wavelength were markedly decreased, and AF vulnerability was increased (Wijffels et al., 1995). Similar changes occur after AF-induction lasting 4 days-16 weeks (Table 1). Chronic atrial regular tachypacing, for 24 hr-18 weeks, produced similar electrical remodelling in other species (Table 1). The ERP-shortening occurred in left and right atria and pulmonary veins (Tang et al., 2006) and correlated with both atrial tachypacing duration (Lee et al., 2000) and AF vulnerability (Morillo et al., 1995). It also markedly decreased wavelength whether or not conduction velocity decreased (Table 1). Furthermore, chronic atrial tachypacing increased the dispersion of ERP (Fareh et al., 2001) and AFCL (Gaspo et al., 1997), and produced atrial hypertrophy and fibrosis (Zhao et al., 2010). Each of these promotes reentry, and multiple wavelet reentry was mapped in-vivo (Gaspo et al., 1997; Li et al., 2000).

3.1.7. Clinical models of AF

In patients, a history of chronic AF typically was associated with decreased atrial ERP in-vivo (Kojodjojo et al., 2007) and in-vitro (Workman et al., 2001), and decreased conduction velocity (Kojodjojo et al., 2007) and AFCL (Fujiki et al., 2001). It was also associated with increased APD restitution slope (Kim et al., 2002), and with ERP-dispersion (Kojodjojo et al., 2007) and electrogram fractionation (Kumagai et al., 1991). The concordance between these and the AF/atrial tachypacing-induced changes in the animal models (Table 1) suggests that AF-induced atrial remodelling, probably promoting reentry, occurs in humans also. The ionic mechanisms of the ERP-shortening are probably primarily an increased I\(K1\) and constitutively active I\(K_{ach}\), and altered intracellular Ca\(^{2+}\)-handling, as identified in studies from several research groups, e.g. (Van Wagoner et al., 1997; Bosch et al., 1999; Workman et al., 2001; Dobrev et al., 2005).
and reviewed in (Workman et al., 2008). An increase in \( I_{\text{KS}} \) might also be involved (Caballero et al., 2010). A decreased systolic intracellular \( \text{Ca}^{2+} \) transient, causing contractile dysfunction, may involve a loss of atrial T-tubules, in sheep (Lenaerts et al., 2009). Furthermore, an increase in diastolic sarcoplasmic reticular \( \text{Ca}^{2+} \) leak (Neef et al., 2010) and in “late” \( I_{\text{Na}} \) (\( I_{\text{NaL}} \)) (Sossalla et al., 2010), both having the potential to cause afterdepolarisations, were associated with human chronic AF. However, it is unclear whether atrial remodelling from chronic AF or atrial tachypacing alters the propensity to afterdepolarisations. AF has been induced acutely in patients, using atrial tachypacing for necessarily brief periods (5-10 min). This caused reversible shortening of atrial ERP and AFCL (Table 1), which was dependent on tachypacing stimulus rate (Yu et al., 1998) and may have involved acute intracellular \( \text{Ca}^{2+} \)-induced inactivation of \( I_{\text{Cal}} \), rather than the type of electrical remodelling that results from chronic AF. Nevertheless, this in-vivo model of acute AF has been used extensively to study electrophysiological mechanisms of anti-arrhythmic drugs.

3.2. Model- and disease-dependence of arrhythmia mechanisms and potential drug effects
Among the differing animal models of AF in section 3.1, and very likely, therefore, the clinical disease states they represent, there are wide variations in the atrial electrophysiological changes and mechanisms promoting this arrhythmia, as shown by Table 1. Anti-arrhythmic drugs that target reentrant or non-reentrant mechanisms may be expected, therefore, to affect AF differently depending on the disease state in question. Such drugs, either in clinical use or under investigation, have thus been tested in a variety of in-vivo models.

4. Drug types for AF termination and prevention: conventional anti-arrhythmics; upstream therapy; investigational
4.1. Pharmacological management of AF with Vaughan Williams class drugs
Pharmacological treatment of patients with AF is aimed initially at protection against thromboembolic events, with anticoagulants. The focus is then either to restore sinus rhythm (rhythm control), or to limit the high ventricular rates resulting from the rapid atrial activation, by inhibiting atrioventricular nodal conduction (rate control). Rhythm control, with anti-arrhythmic drugs, is the long term goal in patients for whom rate control offers inadequate symptomatic relief, or in severely compromised patients (Camm et al., 2010). Anti-arrhythmic drugs are conventionally grouped according to their broad mechanism of action (Vaughan Williams, 1984), namely, \( \text{Na}^{+} \) channel blockade (class I), \( \beta \)-adrenoceptor antagonism (II), action potential prolonging (III), and \( \text{Ca}^{2+} \) channel blockade (IV). Many drugs that prevent AF possess activity in more than one class, and some in none. Nevertheless, this classification serves as a useful basis for assessing and comparing electrophysiological effects of drugs with broadly related activities in the various in-vivo models of AF. The current European Society of Cardiology guidelines for the management of AF (Camm et al., 2010) recommends the use of certain drugs from each of these classes for rhythm and/or rate control, depending on the patient’s disease state.

4.2. Potential pharmacological management of AF with non-Vaughan Williams class drugs
A variety of non-Vaughan Williams class drugs in clinical use, as well as some naturally occurring substances, can prevent or delay atrial structural remodelling associated with hypertension or heart failure. These “upstream therapies”, which include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, aldosterone antagonists, statins, and poly-unsaturated fatty acids, might deter new onset AF or its progression to permanent AF. Of these agents, the European Society of Cardiology recommends ACE inhibitors, angiotensin receptor blockers and statins to be considered for the treatment of AF, depending on disease state (Camm et al., 2010).

4.3. Investigational drug types and rationale for development
Numerous drugs tested in models of AF have either been approved for the treatment of cardiovascular diseases not including AF, or are currently under investigation for potential clinical use including for AF, or are intended purely for experimental use. These drugs are termed “investigational”. Recent development of drugs for rhythm control has focussed on “atrial-selective” and “multi-channel blocking” properties. Atrial-selectivity, in an attempt to avoid experimental use. These drugs are termed “investigational”. Recent development of drugs for rhythm control has focussed on “atrial-selective” and “multi-channel blocking” properties. Atrial-selectivity, in an attempt to avoid
4.4. The need to assess and compare in-vivo mechanistic data on each drug type

The vast majority of Vaughan Williams class drugs and upstream therapies currently recommended for the treatment of patients with AF has been studied extensively in in-vivo models of AF. Furthermore, investigational drugs, and many Vaughan Williams class drugs no longer in widespread use, as well as some drugs which have been withdrawn, were also tested in such models. To improve our overall understanding of anti-arrhythmic mechanisms of drugs having related, as well as unique actions, electrophysiological effects of drugs from all of these categories are examined in detail, below, where in-vivo mechanistic data are available.

5. Class I drugs (Na\(^+\) channel blockers): in-vivo electrophysiological mechanisms of AF termination

5.1. Sub classification of class I drugs, and clinical use in AF

Class I drugs are divided into subclasses a, b and c, according to their effects on the ECG and ventricular conduction, APD and ERP (Vaughan Williams, 1984). The 1\(^{st}\) available, quinidine, procainamide and disopyramide were designated Ia; lidocaine designated Ib. The subsequently developed class Ic drugs include flecainide, propafenone, pilsicainide and moricizine. Cibenzoline has class Ia and Ic activity. Of these drugs, the current European Society of Cardiology guidelines recommends that flecainide and propafenone can be used, in patients without coronary artery disease or heart failure, for converting short duration or recent onset AF, for reducing AF recurrence following cardioversion, and also for long term rhythm control (Camm et al., 2010). Quinidine is now rarely used owing to risk of ventricular pro-arrhythmia from prolongation of the QT interval, and disopyramide is also rarely used except for cholinergic AF (Camm et al., 2010).

5.2. Inhibition of leading circle reentry by class I drugs

Atrial electrophysiological effects of each of these drugs has been studied in in-vivo models of AF. These effects are summarised in Table 2, from which several notable broad patterns emerge.

In keeping with the main recognised action of class I drugs to block I\(_{\text{Na}}\), the conduction velocity was reduced in the majority of studies, presumably by decreasing action potential maximum upstroke velocity. Most studies were in dogs, usually using cholinergic stimulation- or atrial injury-induced AF, and chronic AF/atrial tachypacing was studied in dogs and goats. The primary mechanism of AF in each of these models is reentry (see section 3.1). In cholinergic AF and chronic AF/atrial tachypacing, reentry was caused by a marked decrease in wavelength, from ERP-shortening with little or no concurrent change in conduction velocity (see Table 1). The chronic ventricular tachypacing model of heart failure, in which non-reentrant mechanisms may be more prominent, was not used. All class I drugs terminated AF, with varying efficacies, in most of the models and species studied, but tended not to decrease the vulnerability to its re-induction (Table 2). Also, all drugs, irrespective of model or species, increased AFCL where measured, without exception. The AFCL increase, in all the dog cholinergic AF studies, was associated with an increase in atrial ERP and wavelength (Table 2). This represents a partial or full reversal by the drugs of the decrease in ERP and wavelength which was caused by cholinergic stimulation, that was larger than the associated decrease in conduction velocity. Several class I drugs (e.g., flecainide, propafenone, quinidine) inhibit currents such as I\(_{\text{Kr}}\) or I\(_{\text{KACa}}\), in addition to I\(_{\text{Na}}\). Such K\(^+\) current inhibition may be expected to increase atrial ERP and/or wavelength by increasing APD. However, inhibition of I\(_{\text{Na}}\) alone can also increase atrial ERP in the absence of an increase in APD, thus causing post-repolarisation refractoriness. For example, pilsicainide, which may block I\(_{\text{Na}}\) without also blocking K\(^+\) channels, produced post-repolarisation refractoriness in a dog model of cholinergic AF (Kanki et al., 1998). The effect of pilsicainide, and also of flecainide (Wang et al., 1992) and propafenone (Wang et al., 1993) was use-dependent, i.e., ERP was prolonged preferentially at high atrial rates, such as those encountered during AF. The mechanism of induction of post-repolarisation refractoriness likely involves a depression of I\(_{\text{Na}}\) reactivation and an increase in the diastolic threshold of excitation. Several I\(_{\text{Na}}\) blockers, particularly those with rapid unbinding kinetics, may produce post-repolarisation refractoriness in an atrial-predominant manner (Burashnikov & Antzelevitch, 2010). The effect of class I drugs to increase wavelength, by whatever ionic mechanism, in the canine cholinergic AF models is consistent with an anti-reentrant mechanism from an increase in wavelength beyond the available pathlength, according to the concept of leading circle reentry (Figure 1). Consistent with that, procainamide and propafenone (Wang et al., 1993), and flecainide (Wang et al., 1992) increased the size and decreased the number of reentry circuits in this model, and propafenone inhibited macro-reentry without affecting focal AF (Niu et al., 2009). In the non-cholinergic AF models, by contrast, no class 1 drug increased wavelength, and some even reduced it, e.g., flecainide and cibenzoline (Wijffels et al., 2000), despite increasing AFCL and terminating AF. This indicates that suppression of leading circle reentry may not be sufficient alone to explain anti- arrhythmic effects of I\(_{\text{Na}}\) blockers in these models.

5.3. Inhibition of spiral wave reentry by I\(_{\text{Na}}\) blockade
An alternative explanation was provided using the goat model of chronic AF, and the concept of spiral wave reentry. Quinidine, cibenzoline and flecainide each were shown to increase not wavelength, but the “temporal excitable gap” (Wijffels et al., 2000). This was calculated as AFCL minus the ERP recorded during AF, the earliest moment at which a premature impulse could capture the fibrillating atrium (Figure 1). It was proposed that the increase in AFCL that widened the excitable gap was caused by a preferential slowing by the drugs of high-curvature wavefronts, due in turn to the reduction in the availability of the source current, I_{Na}. This should increase spiral wave reentry core size and decrease reentry rate, and allow wavelets to fuse and decrease in number, rather than fragment. In support, cibenzoline increased reentry wavelet “linking”, i.e., the number of consecutive waves propagating in the same direction, and decreased wavelet “fractionation” (Shan et al., 2004), in this model. Mathematical modelling supports the idea that inhibiting I_{Na} alone is sufficient to terminate AF by suppressing spiral wave reentry. Thus, a simulated reduction in I_{Na} increased the size of generator spirals and slowed their rotation rate by reducing excitability and conduction velocity, despite also decreasing wavelength (Nattel et al., 2003). Mathematical modelling has also highlighted the potential for atrial-selective termination of spiral wave reentry by I_{Na} inhibition (Pandit et al., 2010). The termination of AF by slowing spiral wave reentry is likely not exclusive to the AF/atrial tachypacing models of AF, since in an in-vitro study of cholinergic (acetylcholine-induced) AF, pilsicainide increased the reentry core perimeter associated with an increase in the temporal excitable gap, as well as increasing ERP (Kawase et al., 2003). Several class I drugs were studied in canine atrial injury models (Table 2) and, in each case, increased atrial ERP. Atrial wavelength was measured in one study, and was unchanged by quinidine, perhaps suggestive of suppression of spiral wave reentry. The only model in which AF was not terminated was atrial ischaemia. This intervention substantially decreases the conduction velocity (Table 1), and flecainide did not decrease it further (Table 2).

5.4. Clinical mechanistic studies of class I drugs
Atrial electrophysiological effects of several class I drugs were also studied in patients (Table 2). Where it was possible to measure the effect on ERP after conversion of brief episodes of induced AF (acute atrial tachypacing: shortens ERP and AFCL; Table 1), neither procainamide nor propafenone increased ERP, yet they decreased AF duration. Cibenzoline and flecainide increased AFCL and terminated AF. In one study (Brugada et al., 1993) atrial epicardial mapping was possible in one patient, and cibenzoline fused multiple reentry wavelets into a single broad wavefront. These clinical data are consistent with suppression of AF not involving long term atrial remodelling, potentially by inhibition of spiral wave reentry since ERP did not increase. By contrast, in patients with chronic AF (also associated with ERP- and AFCL-shortening; Table 1), disopyramide, flecainide and propafenone increased atrial ERP. The ERP increase by flecainide was associated with APD increase and post-repolarisation refractoriness (Kirchhof et al., 2005). Procainamide, cibenzoline, flecainide and propafenone also increased AFCL (Table 2). Procainamide decreased the number of pulmonary vein ectopic beats (Chen et al., 1999), and a decrease in atrial electrogram fractionation was also observed in several studies (Brugada et al., 1993; Ishibashi et al., 1995; Tuan et al., 2010). It is conceivable, therefore, that class I drug-induced ERP increase in patients with chronic AF could contribute to suppression of leading circle reentry.

5.5. Potential suppression of non-reentrant arrhythmic activity by class I drugs
Anti-arrhythmic effects of some class I drugs might involve a contribution from a suppression of non-reentrant arrhythmic activity. For example, in mouse ventricular cells in-vitro, flecainide reduced the incidence of isoprenaline-stimulated triggered beats, associated with a reduction in the incidence of spontaneous Ca^{2+} release from the sarcoplasmic reticulum (Watanabe et al., 2009). However, such a mechanism has yet to be demonstrated in atrium.

6. Class II drugs (β-blockers): electrophysiological mechanisms of AF suppression in-vivo
6.1. Clinical use of β-blockers in AF
Beta-adrenoceptor antagonists (β-blockers), such as the β1-blockers esmolol and metoprolol, and the β1/β2-blocker propranolol, currently are recommended mainly for rate control and for preventing post-cardiac surgery AF. Carvedilol, a β1/β2/α1-blocker, is also recommended for rate control. However, some β-blockers are also indicated for long term rhythm control, especially in exercise-induced AF (Camm et al., 2010). There are relatively few studies of atrial electrophysiological mechanisms of β-blockers pertaining to rhythm control using in-vivo models of AF; summarised in Table 3.

6.2. Studies of acute β-blockade in models of atrial ERP-shortening and reentry
β-blockers suppressed AF induced by a variety of interventions (Table 3). Their effects on atrial ERP, however, were reported in only 3 studies; of chronic AF in goats, acute atrial tachypacing in patients (both of which feature atrial ERP-shortening; Table 1), and acute atrial ischaemia in dogs. In the goat study, propranolol was delivered either before or after
AF induction. It had no effect on ERP before AF, i.e., in the absence of atrial electrical remodelling; consistent with its lack of effect on ERP or conduction velocity in dogs in sinus rhythm (Rensma et al., 1988). Furthermore, its continuous delivery during the first 24 hr of AF did not prevent a marked AF-induced shortening of ERP and AFCL during that time (Wijffels et al., 1997). Moreover, when propranolol was administered acutely after AF had become persistent, i.e., after atrial remodelling, it did not reverse the effects of remodelling: ERP and AFCL were unchanged. Whether this drug affected AF vulnerability or duration was not stated. In the human study, propranolol again had no effect on atrial ERP before AF-induction, and also did not prevent ERP-shortening caused by the brief (~10 min) episode of induced AF. It is possible, therefore, that the anti-arrhythmic action of acute β-blockade in these models does not involve inhibition of reentry. However, data on conduction velocity and wavelength, and ultimately activation mapping during AF, are required to confirm that. By contrast, suppression of atrial ischaemia-induced AF, by the β/β₂-blocker nadolol, might involve inhibition of leading circle reentry, since it increased atrial ERP and conduction velocity (Table 3).

6.3. Inhibition of non-reentrant activity by acute β-blockade
In the local nerve-stimulation studies (Table 3), esmolol and propranolol decreased vulnerability to pulmonary vein repetitive focal activity and to atrial premature depolarisations. This could involve inhibition of abnormal automaticity, afterdepolarisations or reentry induced by combined adrenergic-cholinergic activation. A suppression of pulmonary vein electrical activity by propranolol was also reported in patients with paroxysmal AF (Chen et al., 1999). In-vitro studies of pulmonary vein/atrial preparations from dogs (Patterson et al., 2005) or rats (Doisne et al., 2009) suggest that β₁-blockade could suppress EADs or abnormal automaticity produced by local nerve stimulation or noradrenaline, respectively. Numerous studies, mainly in-vitro and reviewed in (Workman, 2010) indicate that β-blockers can prevent catecholamine-induced non-reentrant activity, mainly by inhibiting phosphorylation of proteins involved in intracellular Ca²⁺-handling including Ca²⁺ channels and phospholamban, and thus decreasing I_{Ca,L} and excessive Ca²⁺-loading. Consistent with these studies, in chronic ventricular tachypacing-induced heart failure, which elevates circulating catecholamines (Moe et al., 1989) and promotes Ca²⁺-overload and DADs (Stambler et al., 2003), propranolol decreased AF vulnerability (Table 3).

6.4. Pharmacological remodelling by chronic β-blockade
A potential reentry-inhibiting mechanism of β-blockers is an atrial ERP-prolonging adaptation to their long-term use, so-called pharmacological remodelling. This was demonstrated in rabbits in sinus rhythm, after 6 days of treatment with either a β₁- or a β₁/β₂-blocker (Raine & Vaughan Williams, 1981), and also was independently associated with β₁-blocker therapy in patients in sinus rhythm (Workman et al., 2003b; Workman, 2010). Among the studies in Table 3, β-blockers were probably given acutely in all but the chronic AF model (maximum 3-day treatment) and should not be expected, therefore, to have exerted their effects on AF by such pharmacological remodelling. While it is possible that a sufficiently long period of β-blockade to cause pharmacological remodelling still might not overcome ERP-shortening from AF-induced electrical remodelling, the ERP increase in the absence of AF (Raine & Vaughan Williams, 1981; Workman et al., 2003b) could conceivably contribute to maintenance of sinus rhythm.

7. Class III drugs (APD-prolonging): in-vivo electrophysiological mechanisms of AF termination and prevention
7.1. Drug types, clinical uses in AF, and potential risks
The original class III drug, amiodarone, is the most effective available anti-arrhythmic drug. It has multiple actions including inhibition of numerous ion currents (I_{Na}, I_{To}, I_{Ca,L}, I_{Ca,T}, I_{Kp}, I_{Kr}, I_{Ks}, I_{KNa}, I_{Na/Ca}, I_{K1}, I_{KACH}) and adrenergic/cholinergic receptors. Amiodarone is currently recommended for converting recent onset or persistent AF, for preventing AF recurrence, for long term rhythm control, and also for rate control when other measures are unsuccessful or contraindicated (Camm et al., 2010). However, amiodarone has serious side effects, and while it can be used in patients with structural heart disease, it may adversely affect nearly every organ. Dronedarone, its non-iodinated analogue, is safer but less efficacious (Piccini et al., 2009), and is recommended for long term rhythm and rate control in patients with non-permanent AF who don’t have severe or unstable heart failure. Other class III drugs such as dofetilide or ibutilide are recommended for converting AF or atrial flutter (Camm et al., 2010), but risk ventricular pro-arrhythmia, most likely from their inhibition of I_{Kr}. Sotalol is racemic, and the d,l-form, used clinically and in most in-vivo models of AF, has both class III (I_{Kr}-blocking) and II (β₁/β₂-antagonising) action. It may be used for preventing AF recurrence, but is also limited by QT prolongation. Vernakalant, an I_{Kr}/I_{Na}/I_{KACH} blocker, also has class III action and was recently recommended for approval by the European Medicines Agency for treating new onset AF (Camm et al., 2010).

7.2. Suppression of leading circle reentry by class III effect
Atrial electrophysiological effects of most of these drugs were studied in-vivo in animal models of a variety of causes and risk factors for AF. All drugs could terminate AF in one or more model, and generally increased atrial ERP and AFCL.
The ERP increase often was associated with, and likely resulted from, prolongation of terminal repolarisation, e.g., of APD_{90} by amiodarone (Ashikaga et al., 2006) or ibutilide (Vereckei et al., 2001) in dogs, or by amiodarone (Pandozi et al., 2003) or sotalol (Kirchhof et al., 2005) in patients. The APD increase is generally ascribed to the effect of class III drugs to block atrial I_{Kr}. However, I_{Kr} exists also in ventricle, and ventricular APD increase, e.g., by dofetilide (Chandra et al., 2004), risks QT prolongation and ventricular pro-arrythmia. The atrial ERP increase frequently was reverse use-dependent, i.e., stronger at low versus high rates (Nattel et al., 1998), one reason why class III drugs can fail to terminate AF yet can prevent its induction (Derakhchan et al., 2001). Class III drugs generally had little or no effect on atrial conduction velocity in animal models, but decreased it in patients with chronic AF, e.g., with amiodarone or ibutilide (Table 4). Atrial wavelength increased in most studies, always associated with ERP increase, suggestive of a general class III effect that could suppress leading circle reentry (Figure 1). In support, sotalol, which increased ERP and wavelength, also increased reentry circuit size and decreased their number, in cholinergic AF (Wang et al., 1993). Dofetilide, ibutilide and nifekalant also increased ERP and/or wavelength in that model (Table 4). [insert Table 4]

7.3. Loss of class III effect in electrical remodelling

There are exceptions to the rule of atrial ERP increase by class III drugs, however, particularly with the goat chronic AF model (Table 4). Thus, in all reports using this model, any drug effect to increase ERP either before AF or within the first 24 hours of AF, was attenuated or lost subsequently, e.g., with amiodarone (Linz et al., 2007), dofetilide (Blaauw et al., 2004), or ibutilide or sotalol (Duytschaever et al., 2005). Furthermore, in 2 studies, when ERP did not increase, neither did wavelength (Wijffels et al., 1999; Blaauw et al., 2004). Despite this, AFCL-increasing and anti-AF effects could persist (Wijffels et al., 1999; Linz et al., 2007). The reason for the loss of class III effect in the remodelled atria is unclear. However, it could be species-specific, since in dogs, both amiodarone and sotalol reversed chronic atrial tachypacing-induced AF and ERP-shortening when drug delivery was started after electrical remodelling (Shinagawa et al., 2003; Ashikaga et al., 2006; Sakamoto et al., 2009). Nevertheless, an attenuation of class III effect could occur in humans, since sotalol increased ERP less in patients with chronic AF than in those in sinus rhythm (Tse & Lau, 2002).

7.4. Possible class III inhibition of spiral wave reentry

Anti-arrhythmic, but non-ERP-prolonging, effects of class III drugs in the goat models suggest electrophysiological mechanisms other than inhibition of leading circle reentry. Termination of AF with increased AFCL, and not wavelength, by the class I drugs quinidine, cibenzoline and flecaainide (Table 2), each of which may block I_{ Kr}, as well as I_{Na}, was considered due to inhibition of spiral wave reentry (see section 5.3). Such a mechanism is also possible for class III drugs (Figure 1). In support, d-sotalol (specific I_{Kr} blocker) had no effect on ERP or wavelength in the AF-remodelled atrium, yet terminated AF with an approximate doubling of the temporal excitable gap, an effect considered as potentially resulting from preferential slowing of high curvature reentry wavefronts (Wijffels et al., 2000).

7.5. Clinical mechanistic and other studies of class III drugs

Several class III drugs were studied in patients (Table 4). Amiodarone and sotalol decreased the incidence and duration of acutely-induced AF episodes, despite not inhibiting the ERP-shortening that these caused. However, in patients with chronic AF, which also shortens ERP, amiodarone increased ERP in all 4 studies, including in pulmonary vein (Rostock et al., 2005). AFCL was measured in 2 of those, and was increased in both. Ibutilide’s effect to terminate AF in patients was also accompanied by increased ERP, as well as decreased conduction velocity and increased AFCL. Sotalol increased ERP in each of 2 studies in patients with chronic AF, and also increased AFCL. Reports of class III drug studies using in-vivo models of AF that produce no clear atrial ERP-shortening (see Table 1), e.g., heart failure, atrial dilation, hypertension, adrenergic stimulation and atrial ischaemia, are relatively few (Table 4). In a single study using the dog ventricular tachypacing model of heart failure, dofetilide increased atrial ERP, wavelength and AFCL, with no change in conduction velocity, and blocked reentry and terminated AF (Li et al., 2000). In dogs with chronic atrial dilation, or atrial injury, dofetilide terminated AF, associated with increased ERP and AFCL and decreased conduction velocity, but it was unable to prevent ischaemia-induced AF. In a transient asphyxia model of AF, amiodarone or sotalol decreased AF vulnerability and duration, and amiodarone terminated aconitine-induced AF, presumably by inhibiting triggered activity.

7.6. Recent drugs with class III action: dronedarone and vernakalant

Dronedarone and vernakalant each have class III action, but data on their atrial electrophysiological mechanisms of action in in-vivo models of AF are lacking. Dronedarone (SR 33589), like amiodarone, inhibits I_{Na} in a frequency-dependent manner, I_{CaL}, various K^+ currents, and β-adrenoceptors, and it may block I_{KACH} more potently than amiodarone (Ravens, 2010). In dogs in sinus rhythm, intravenous dronedarone increased atrial and ventricular ERP (Manning et al., 1995). A lack of change in ventricular ERP with decreased APD has also been reported (Verdun et al., 1999). In dog atrial tissues in-vitro, acute dronedarone increased atrial ERP, but did not attenuate acetylcholine-induced ERP-
shortening or AF. Acute amiodarone, by comparison, inhibited the ERP-shortening and AF (Burashnikov et al., 2010a). Dronedarone also suppressed dofetilide-induced EADs and ouabain-induced DADs in isolated Purkinje fibres (Varro et al., 2001). In patients with recurrent AF, dronedarone was superior to placebo in maintaining sinus rhythm, but electrophysiological mechanisms were not studied (Singh et al., 2007). Vernakalant increased atrial (and not ventricular) ERP in patients with no history of AF (Dorian et al., 2007). In patients with AF, vernakalant was efficacious in acutely terminating the arrhythmia, but atrial electrophysiological mechanisms were not studied (Roy et al., 2008). Vernakalant may be both atrial-predominant, since it blocks $I_{Kur}$ and disease-specific, since it blocks $I_{Na}$ preferentially at high rates and in depolarised tissue. Mathematical modelling suggested that rapidly-unbinding $I_{Na}$ blockers such as vernakalant may terminate cholinergic AF, not by increasing atrial wavelength, but rather by decreasing atrial conduction velocity and spiral wave reentry rate, and destabilising “primary generator rotors” (Comtois et al., 2008).

7.7. Pharmacological remodelling by amiodarone

Another potentially anti-arrhythmic mechanism of a class III drug is pharmacological remodelling by amiodarone, perhaps analogous to that by chronic β-blockade (Workman, 2010). Thus, chronic (6 weeks) amiodarone treatment in dogs increased APD$_{90}$ and ERP and caused post-repolarisation refractoriness, more so in isolated atrial than ventricular tissues, and inhibited acetylcholine-induced AF (Burashnikov et al., 2008). Increased pulmonary vein APD also was reported in this model (Sicouri et al., 2009), along with prevention of isoprenaline-induced DADs.

8. Class IV drugs (Ca$^{2+}$ channel blockers): electrophysiological effects in in-vivo models of AF

8.1. Clinical use of Ca$^{2+}$ channel blockers for rate control, and loss of effects on electrical remodelling

The Ca$^{2+}$ channel blockers verapamil and diltiazem are currently recommended for ventricular rate control (Camm et al., 2010). However, their effects on atrial rhythm have also been studied, and in a wide range of in-vivo models of AF, along with those of other Ca$^{2+}$ channel blockers: bepridil and efonidipine (Table 5). Ca$^{2+}$ channel blockers prevented AF or inhibited its induction in 7 of 12 reports, but also could have no effect, or even promote AF (in 4 studies, each in a different model). Most studies were of verapamil and diltiazem, which block $I_{Ca,T}$. The most consistent Ca$^{2+}$ channel blocker effect was that of verapamil to increase atrial ERP in acute atrial tachypacing-induced AF in patients (Table 5).

Thus, in each of 3 studies, verapamil, given just before an ~10 min episode of AF, attenuated or prevented AF-induced ERP-shortening. However, verapamil effects on AF were inconsistent, with either suppression (Daoud et al., 1997; Yu et al., 1998) or promotion (Sticherling et al., 2002). Abrupt increase in atrial rate, e.g., as occurs at the onset of an episode of AF in patients, rapidly elevates atrial intracellular Ca$^{2+}$. By accelerating $I_{Ca,L}$ inactivation, this Ca$^{2+}$ elevation may rapidly shorten ERP. A reduction in $I_{Ca,L}$ amplitude by verapamil could attenuate intracellular Ca$^{2+}$ elevation, perhaps explaining its effect to attenuate such ERP-shortening in patients. Alternatively, inhibition of $I_{Kr}$ (Zhang et al., 1999) and/or $I_{Kur}$ (Gao et al., 2004) by verapamil might also contribute to the increase in ERP. Verapamil also increased ERP early on during atrial tachypacing in each of 2 studies using the dog chronic atrial tachypacing model (Table 5). An increase in wavelength (Ohashi et al., 2004) and a decrease in AF vulnerability (Lee et al., 2000) also were found. However, these effects of verapamil on ERP, wavelength and AF were lost after 1 or 2 weeks of continuous atrial tachypacing, despite daily drug administration. There was also a corresponding lack of effect of diltiazem on AF or atrial electrophysiology after 1 week of atrial tachypacing in this model (Table 5). One explanation for the time-dependent loss of effect of these drugs may be the fact that long term remodelling shortens ERP by different mechanisms than short term remodelling, e.g., by (potentially over-riding) increases in $I_{K1}$ and $I_{KACCh}$ (Workman et al., 2008). However, the ERP-prolonging effect of efonidipine or bepridil, by contrast with that of verapamil, was not lost (Table 5). Both drugs block $I_{Ca,T}$ in addition to $I_{Ca,L}$, and since a continuous inward leak of Ca$^{2+}$ via $I_{Ca,T}$ may contribute to long term atrial remodelling (Fareh et al., 2001), the block of $I_{Ca,T}$ by these drugs might explain the persistence of their atrial electrophysiological/anti-arrhythmic effects.

8.2. Potential of Ca$^{2+}$ channel blockers to inhibit non-reentrant AF

Verapamil was also tested in the dog chronic (2-6 week) ventricular tachypacing model of heart failure which, by contrast with the chronic AF/atrial tachypacing models, does not shorten ERP (Table 1) and the AF it produces likely involves non-reentrant activity. In each of 2 studies (Table 5), verapamil could terminate AF. It had no consistent effect on AFL (Stambler et al., 2003), and preferentially prevented AF due to atrial “drivers” rather than to “irregular activation” (Ryu et al., 2005). These data, contrasting with the relative lack of anti-AF action of $I_{Ca,L}$ blockade in the chronic AF/atrial tachypacing models, are in line with a suppression of non-reentrant atrial arrhythmic activity involving $I_{Ca,L}$. Data are sparse on atrial electrophysiological mechanisms of Ca$^{2+}$ channel blockers in most of the other models of AF studied, namely, cholinergic stimulation, atrial ischaemia, acute atrial dilation, and transient asphyxia (Table 5), and no consistent patterns emerged. Furthermore, AF was either promoted, inhibited or unchanged among these models. In patients with a
history of AF, atrial electrophysiological effects of Ca\(^{2+}\) channel blockers were studied only in those with paroxysmal AF. The ERP, wavelength and AFCL were not measured, and Ca\(^{2+}\) channel blocker effects on AF were inconsistent. Thus, verapamil either increased atrial dominant frequency, suggestive of a pro-arrhythmic effect by promoting high frequency zones of activation (Kushiyama et al., 2010), or decreased the incidence of pulmonary vein ectopic activity and “burst AF” (Chen et al., 1999).

9. Upstream therapies and other clinically available agents: in-vivo mechanisms

9.1. Atrial electrophysiological mechanisms of upstream therapies

9.1.1. ACE inhibitors and angiotensin receptor blockers

ACE inhibitors and angiotensin receptor blockers are currently recommended for consideration for primary prevention of AF in patients with heart failure and reduced left ventricular function, or with hypertension, and for secondary prevention in patients who have recurrent AF despite receiving anti-arrhythmic drugs (Camm et al., 2010). Several ACE inhibitors and angiotensin receptor blockers in clinical use have been studied in in-vivo models of AF, either chronic AF/atrial tachypacing or left ventricular dysfunction, in a variety of species (Table 6).

These drugs were usually anti-arrhythmic, decreasing AF vulnerability, incidence or duration in 8 of 11 studies, irrespective of model type. With remarkable consistency, atrial ERP was unaffected by any ACE inhibitor or angiotensin receptor blocker in either model type. Candesartan also had no effect on the time course of chronic AF-induced shortening of ERP or AFCL (Hall et al., 2010). The duration of AF or atrial tachypacing in all of the chronic AF/atrial tachypacing studies (Table 6) was ≥1 week. However, it should be noted that, in a study of short term (3 hr) atrial tachypacing, either candesartan, or the ACE inhibitor captopril, prevented shortening of the atrial ERP (Nakashima et al., 2000). ACE inhibitor/angiotensin receptor blocker effects on atrial global conduction velocity were less consistent, either leaving it unchanged or increasing it (Table 6). However, no ACE inhibitor or angiotensin receptor blocker decreased conduction velocity. When measured, atrial wavelength was unchanged, always coincident with a lack of change in conduction velocity (Table 6), but wavelength-increase may be expected in the 2 studies in which conduction velocity increased, since ERP was unchanged. An increase in wavelength could inhibit leading circle reentry. However, confirmatory activation mapping evidence with these drugs is lacking. Nevertheless, in the chronic ventricular tachypacing model, enalapril decreased atrial conduction velocity-dispersion, i.e., attenuated local conduction disturbances caused by heart failure (Li et al., 2001). Decreased electrical heterogeneity should oppose reentry, by preventing unidirectional conduction block (Figure 1). The improved conduction was associated with, and likely caused by, attenuation of heart failure-induced atrial fibrosis (Li et al., 2001). That was unlikely to have involved any effect of the drug to improve coronary flow, since fibrosis was unaffected by a non-ACE inhibitor vasodilator (Li et al., 2001).

ACE inhibitors/angiotensin receptor blockers also inhibited pathological atrial structural remodelling in other studies in which they inhibited AF (Table 6), preventing fibrosis (Anne et al., 2007), myolysis (Li et al., 2007) and hypertrophy (Li et al., 2007). The reduction in fibrosis occurred whether with chronic atrial tachypacing or chronic ventricular tachypacing, despite atrial tachypacing producing substantially less fibrosis than ventricular tachypacing (Everett et al., 2006). Consistent with this, ACE inhibitor therapy was associated with decreased atrial tissue collagen content in patients with chronic lone AF (Boldt et al., 2006). These effects on fibrosis and myolysis add support to an anti-arrhythmic mechanism involving improved conduction, and the atrial anti-hypertrophic action could also inhibit reentry by reducing the available pathlength (Figure 1). The biochemical mechanisms of increased atrial fibrosis in heart failure are incompletely understood, but likely involve induction of mitogen-activated protein kinases as a consequence of renin-angiotensin-aldosterone system activation. The mechanism of suppression of atrial structural remodelling by the ACE inhibitors and angiotensin receptor blockers most likely involves, therefore, inhibition of pathological angiotensin elevation and associated signalling, as shown with enalapril in heart failure-induced AF (Li et al., 2001) and with quinapril and losartan in chronic atrial tachypacing-induced AF (Anne et al., 2007). Whether the anti-arrhythmic effects of ACE inhibitors and angiotensin receptor blockers involve a contribution from reversal of any acute pro-arrhythmic effects of angiotensin is unclear. Acute angiotensin had no effect on atrial conduction velocity, ERP or ERP-dispersion in patients (Kistler et al., 2005). In guinea pig atrial cells, acute angiotensin increased I_{KS} and shortened APD (Zankov et al., 2006). The contribution of I_{KS} to human atrial repolarisation, however, may be relatively small (Workman, 2010). Nevertheless, acute angiotensin might produce EADs, by increasing the production of reactive O\(_2\) species, as shown in rabbit ventricular cells (Zhao et al., 2011).

9.1.2. Aldosterone antagonists

Aldosterone antagonists, e.g., spironolactone, may reduce AF recurrence in patients with hypertension and mild left ventricular dysfunction, but there is currently no recommendation regarding their use as upstream therapy in the prevention of AF (Camm et al., 2010). In the in-vivo models of AF, spironolactone or eplerenone decreased AF vulnerability either in heart failure or chronic atrial tachypacing (Table 6). Spironolactone also prevented atrial
tachypacing-induced atrial fibrosis, apoptosis and myolysis and the associated altered expression of regulatory proteins that could favour extracellular matrix degradation. This could improve local conduction and, coupled with the prevention by spironolactone of atrial hypertrophy (Zhao et al., 2010), might oppose reentry.

9.1.3. Statins

Statins are recommended for consideration for prevention of new-onset AF after cardiac surgery, or in patients with underlying heart disease, particularly heart failure (Camm et al., 2010). Several have been tested in representative animal models, which featured marked atrial fibrosis: pericarditis or heart failure in dogs, and reactive O$_2$ species overproduction in mice. Chronic atrial tachypacing in dogs was also studied (Table 6). In all the dog studies, atorvastatin or simvastatin decreased AF duration and, in each case, increased either ERP, conduction velocity, or both, thus potentially increasing wavelength. However, in the transgenic mouse model, which produced atrial tachycardia rather than AF, rosuvastatin had no effect on ERP, conduction velocity or atrial tachycardia. The prevention by atorvastatin of pericarditis-induced decrease in ERP and conduction velocity is consistent with inhibition of atrial reentry, likely the primary arrhythmia mechanism in this model, and the improved conduction was coupled with decreased fibrosis. Atrial fibrosis and conduction velocity-dispersion were also prevented by simvastatin in the heart failure model. These data point to a contribution from anti-fibrosis to AF suppression by statins. However, numerous additional mechanisms may operate, e.g., improved lipid metabolism, altered membrane fluidity and ion channel conductance, and suppression of atherosclerosis, inflammation, reactive O$_2$ species, endothelial dysfunction and neurohumoral activation (Savelieva et al., 2010).

9.1.4. Poly-unsaturated fatty acids

There is presently no strong clinical evidence to support the use of n-3 (omega-3; fish oil-derived) poly-unsaturated fatty acids in primary or secondary prevention of AF, as discussed in the current guidelines (Camm et al., 2010) and corroborated by a subsequent randomised double-blind, placebo-controlled clinical trial (Kowey et al., 2010). Among a variety of in-vivo animal models, n-3 poly-unsaturated fatty acids either suppressed AF or had no effect, and also exerted minimal effect on atrial electrophysiology (Table 6). Nevertheless, in the 2 dog ventricular tachypacing models, which cause localised atrial conduction disturbances, poly-unsaturated fatty acids reduced atrial conduction velocity-dispersion. In one study, atrial fibrosis was also reduced (Sakabe et al., 2007). Again, such structural effects could oppose reentry. Non-reentry should not be excluded, however, since poly-unsaturated fatty acids inhibited afterdepolarisations in ventricular cells from patients with heart failure, coupled with a lowering of intracellular Ca$^{2+}$ (Den Ruijter et al., 2008). Other putative anti-AF mechanisms of poly-unsaturated fatty acids include plasmalemma stabilisation, vasodilation, and modulation of ion channels or gap junctions. Poly-unsaturated fatty acids may also suppress inflammation, as a result of activation of peroxisome proliferator-activated receptors, and suppress reactive O$_2$ species production (Savelieva et al., 2010).

9.1.5. Other potential upstream therapies

Fenofibrate and pioglitazone, activators of peroxisome proliferator-activated receptor-$\alpha$ and -$\gamma$, respectively, were studied in heart failure models (Table 6). Only pioglitazone suppressed AF, which was associated with increased conduction velocity, likely from a suppression of atrial fibrosis. The anti-inflammatory drugs prednisone and ibuprofen were studied in a chronic atrial tachypacing model of AF (Table 6). Prednisone decreased AF vulnerability and duration and increased ERP, while ibuprofen had no effect. The anti-oxidant vitamin C was also tested, in 2 studies of chronic atrial tachypacing (Table 6). In the 1st, it attenuated atrial ERP-shortening, but AF was not studied. In the 2nd, vitamin C had no effect on ERP-shortening or AF.

9.2. Atrial electrophysiological mechanisms of digoxin in rate and rhythm control

Digoxin is neither a Vaughan Williams class drug nor upstream therapy. It is a Na$^+$.K$^+$ pump blocker, recommended for rate control at rest (due to its vagotonic effect) (Camm et al., 2010). This drug was studied in a goat chronic AF model, to assess its potential to affect mechanisms of rhythm control and atrial remodelling. Digoxin either moderately increased AF vulnerability and duration, or had no effect (Table 6). It had no effect on atrial ERP, conduction velocity, AFCL or electrogram fractionation (Duytschaever et al., 2000). Such a lack of effect of Na$^+$.K$^+$ pump blockade on atrial electrophysiology in this model is consistent with the reported absence of change in atrial Na$^+$.K$^+$ pump current density in patients with chronic AF (Workman et al., 2003a). However, digoxin delayed AF-recovery after cessation of AF in goats, perhaps by a persistent effect to elevate intracellular Ca$^{2+}$ (Tieleman et al., 1999). Such an effect could theoretically increase AF recurrence in patients after cardioversion. In line with this, digoxin exacerbated AF re-induction and atrial ERP-shortening following acute atrial tachypacing-induced AF in patients (Table 6). It was noted that, because all patients underwent autonomic blockade (Sticherling et al., 2000), the AF-promoting effect of digoxin was more likely due to its effect to increase intracellular Ca$^{2+}$ than to increase vagal tone.
10. Investigational anti-arrhythmic drugs: in-vivo electrophysiological mechanisms of AF termination and prevention

10.1. Types of investigational drugs and AF models studied

Numerous investigational drugs have been studied in in-vivo animal models of AF (Table 7). Many are being tested as potential treatments for AF, and some have already been approved for other conditions. Others were withdrawn, or are intended purely for experimental use. Most studies were in dogs, usually in ERP-shortening, reentry-promoting, models: chronic AF/atrial tachypacing or cholinergic stimulation. Reentry-promoting atrial injury models were also widely used. Relatively few drugs were tested in models of atrial structural remodelling, such as heart failure or pericarditis. This may reflect the primary mechanism of action of most drugs tested: APD-prolonging ion channel blockers. The relatively selective blockers are shown first in Table 7, followed by multi-channel blockers, then gap junction-enhancers and others.

10.2. Investigational ion channel blockers: in-vivo electrophysiological mechanisms

The ion channel blockers as a group increased atrial ERP with remarkable consistency: in 23 of 25 studies in which it was measured (Table 7). Atrial wavelength was increased in 5 of 6 studies, always as a result of ERP-increase, and AFCL was also consistently increased: in 19 of 20 studies. These drugs tended to terminate AF more effectively than inhibit its induction.

10.2.1. Selective ion channel blockers

Of the selective ion channel blockers, three: DPO-1 (a diphenylphosphine oxide) and tertiapin (a bee venom peptide) target I_Kr or I_KaCh and are thus atrial-predominant. In line, AF-termination by each was accompanied by an increase in atrial ERP without effect on ventricular ERP. This is desirable as it minimises ventricular pro-arrhythmia risk from ventricular afterdepolarisations. The likely anti-AF mechanism was suppression of reentry by the ERP increase. However, NIP-151 and tertiapin also terminated aconitine-induced AF (Table 7), presumably by suppressing afterdepolarisations. The selective I_Kr blockers all terminated AF and prolonged atrial ERP, except for almokalant. However, several also prolonged the QT interval and/or ventricular ERP: e.g., almokalant, KCB-328 and MK499. The anti-arrhythmic mechanism presumably involved suppression of reentry, the predominant arrhythmia mechanism in the models used. In support, KCB-328 also decreased ERP-dispersion (Rahme et al., 2001), potentially inhibiting unidirectional conduction block (Figure 1). Atrial flutter was mapped during azimilide (I_Kr/I_Ks block) treatment in the chronic atrial dilation model. Azimilide terminated this arrhythmia by increasing ERP and preferentially decreasing conduction velocity in slowly-conducting zones of atrial reentry circuits (Restivo et al., 2001). It should be noted, however, that since the electrophysiological mechanisms of atrial flutter may differ from those of AF (see section 2.1.2), the effects of azimilide on these arrhythmias also may differ. Azimilide also increased ERP in the cholinergic AF model, terminating AF when AFCL-increase was greatest. Selective I_Ka blockade with HMR 1556 also terminated AF, including in pigs (Table 7). However, it increased ventricular as well as atrial ERP (Nakashima et al., 2004). The aminobenimidazole NS8593 blocks the small conductance Ca^{2+}-activated K^{+} current (I_{SKCa}). An increase in I_{SKCa} may contribute to APD-shortening from rapid atrial pacing (Ozgen et al., 2007). In an in-vivo rat model, NS8593 decreased AF duration (Table 7) associated with, and considered to be caused by, increased ERP as measured in-vitro in the same study. NS8593 did not prolong the QT interval, in guinea pig hearts (Diness et al., 2010). The Na^{+}-H^{+} exchanger current (I_{NaH}) inhibitor cariporide (HOE642) did not affect atrial electrophysiology in a chronic atrial tachypacing model (Table 7). Nevertheless, it prevented atrial ERP-shortening and loss of ERP rate-adaptation due to atrial ischaemia, both effects which could oppose reentry. However, it is presently unclear whether atrial I_{NaH} is altered in AF-remodelling (Workman et al., 2008).

[insert Table 7]

10.2.2. Multi-channel blockers

All the multi-channel blockers (Table 7) inhibit at least one K^{+} current (most commonly I_Kr), and over half block I_Na. Those that block I_KaCh and/or I_KaCh may possess some degree of atrial-predominance: ambasilide, AVE0118, AZD7009, nibentan, NIP-142, SD-3212, SSR149744C, and tedisamil. Furthermore, those which block I_Na with marked voltage-dependence also may be atrial-predominant, by producing greater block in atrium than ventricle, e.g., ranolazine (anti-anginal), AZD7009, and possibly SSR149744C (celivarone; structural analogue of amiodarone). Additional block of I_KaCh, e.g., with ranolazine (Sossalla et al., 2010), could also counterbalance any ventricular APD-prolonging effect of I_Kr block and thus potentially lower pro-arrhythmic risk. For detailed ionic mechanisms of such atrial-predominance, refer to (Ravens, 2010). Most multi-channel blockers terminated AF (Table 7). All except vanoxerine (dopamine transporter antagonist) increased ERP, likely by increasing atrial APD, e.g., AVE0118 (Blauw et al., 2007) and SD-3212. AVE0118 (a biphenyl derivative) did not affect QT (Blauw et al., 2007), consistent with atrial-selectivity. By contrast, ambasilide, AZD7009, nibentan, ranolazine and tedisamil all could increase QT and/or ventricular ERP. Furthermore, the effects of AVE0118 were not lost as electrical remodelling progressed (Linz et al., 2007), unlike those of, for example,
the $I_{Kr}$ blockers d-sotalol and ibutilide (see section 7.3). AVE0118 also attenuated an increase in both ventricular repolarisation-heterogeneity and fibrillation caused by ventricular ischaemia in dogs (Billman & Kukielka, 2008). In Table 7, the consistently increased atrial ERP (and wavelength where measured) suggest an effect of the multi-channel blockers to inhibit leading circle reentry (Figure 1), as considered in the study of AVE0118 (Blaauw et al., 2004). Supporting evidence was provided by mapping: ambisilide (Wang et al., 1994) and nibentan (Fedorov et al., 2000) terminated AF by decreasing the number and increasing the size of co-existing reentrant circuits required to support AF. However, some $I_{Na}$-blocking drugs might inhibit spiral wave reentry (see section 5.3): AZD7009 terminated pericarditis-induced AF by slowing conduction at wavefront “pivot points” (Goldstein et al., 2004), and vanoxerine reduced the “safety factor for conduction” in slow zones of reentry circuits (Matsumoto et al., 2010). Ranolazine’s anti-arrhythmic mechanism was not determined, and an effect to reduce atrial dominant frequency was considered as due to its inhibition of either macro-reentry or focal atrial tachycardia (Kumar et al., 2009). In support of an anti-reentrant mechanism, ranolazine increased atrial ERP and post-repolarisation refractoriness (without affecting ventricular ERP) in dog atria in-vitro (Sicouri et al., 2010). However, ranolazine could also suppress triggered activity, as demonstrated in dog pulmonary veins in-vitro (Sicouri et al., 2008), perhaps by its inhibition of $I_{CaL}$: an effect potentiated in cells isolated from patients with chronic AF (Sossalla et al., 2010). Data are emerging on a synergism between effects of ranolazine and other anti-arrhythmic drugs. In atrial tissues isolated from dogs treated chronically with amiodarone, acute ranolazine produced a synergistic, use-dependent and atrium-predominant depression of $I_{Na}$-dependent action potential parameters, and abolished acetylcholine plus burst pacing-induced AF (Sicouri et al., 2010). Furthermore, acute ranolazine plus acute dronedarone produced post-repolarisation refractoriness in dog atrial tissues, in a synergistic, use-dependent and atrial-predominant manner. This drug combination also markedly reduced the incidence of acetylcholine-induced AF, and of isoprenaline plus high extracellular Ca$^{2+}$-induced DADs and triggered activity in isolated pulmonary vein sleeves (Burashnikov et al., 2010b).

10.3. Gap junction-enhancers
Gap junction-enhancing peptides were tested in a wide range of animal models (Table 7), most of which reduce atrial conduction velocity (see Table 1) and/or increase its dispersion (see section 3.1). Uncoupling of atrial cells by interstitial fibrosis is a prominent feature of some of these models, e.g., ventricular tachypacing-induced heart failure, and pericarditis. However, the contribution to uncoupling from gap junction remodelling in those, or in chronic AF/atrial tachypacing models, is unclear. By contrast, loss of gap junction communication in acute ischaemia is considered to contribute substantially to conduction-slowing and arrhythmogenesis. GAP-134 (small molecule gap junction-modifier) and rotigaptide (stable derivative of the anti-arrhythmic peptide AAP10) increased atrial conduction velocity and did not affect atrial ERP in all in-vivo studies (Table 7). However, any consequent increase in wavelength generally was accompanied by disparate effects on AF: rotigaptide was ineffective in chronic ventricular tachypacing or atrial tachypacing, and GAP-134 suppressed AF in the ventricular tachypacing plus atrial tachypacing model only in animals with minimal atrial dilation. Furthermore, GAP-134 increased atrial dominant frequency and electrogram disorganisation (Laurent et al., 2009), consistent with AF promotion, rather than inhibition. However, in atrial ischaemia or pericarditis, gap junction-enhancers suppressed AF (Table 7). The anti-AF mechanism in ischaemia may have been in part to the decrease in conduction velocity-dispersion, an effect not produced by rotigaptide in the heart failure model, in which AF was not inhibited. The biochemical mechanism of the enhanced gap junction communication likely involved enhanced phosphorylation and/or suppressed dephosphorylation of connexins (Shiroshita-Takeshita et al., 2007b).

10.4. Other investigational drugs
Other investigational drugs include those that affect intracellular Ca$^{2+}$-handling: mibefradil (withdrawn from clinical use), K201 (JTV-519), ryanodine and tetracaine (local anaesthetic); as well as an anti-fibrotic and a 5-hydroxytryptamine antagonist (Table 7). Mibefradil, an $I_{CaL}$ blocker, decreased the duration of chronic atrial tachypacing-induced AF in dogs, associated with an increase in atrial ERP and a decrease in its dispersion (it prevented atrial tachypacing-induced ERP-remodelling), without changing conduction velocity, and consequently increased wavelength. The anti-arrhythmic mechanism may have involved an attenuation of intracellular Ca$^{2+}$-elevation-induced atrial remodelling, by block of inward Ca$^{2+}$ leak via $I_{CaL}$ which, unlike $I_{CaT}$, is not downregulated in atrial tachypacing-remodelling (Yue et al., 1997). K201 (benzothiazepine derivative) has multiple actions: inhibition of $I_{Kr}$, $I_{CaT}$ and various K$^+$ channels, and stabilisation of ryanodine receptor conformation which may reduce a potentially arrhythmogenic diastolic sarcoplasmic reticular Ca$^{2+}$ leak. In-vitro, K201 suppressed AF, associated with an increase in atrial ERP, and with no change in conduction velocity (Table 7). It also prolonged the QT interval, however. The anti-AF mechanism was considered to be inhibition of reentry, the likely predominant cause of AF in the pericarditis model. In support, K201 decreased the vulnerability to carbachol-induced AF in guinea pig hearts in-vitro, associated with atrial ERP-increase, likely from an observed inhibition of $I_{KCh}$ and $I_k$ (Nakaya et al., 2000). However, K201 could also suppress non-reentrant AF since it reduced DAD amplitude or the rate of spontaneous activity, associated with a decreased intracellular Ca$^{2+}$ transient and $I_{Na,Ca}$ in rabbit pulmonary vein isolated cells (Chen et al., 2008). Furthermore, K201 attenuated diastolic spontaneous sarcoplasmic reticular Ca$^{2+}$
release caused by intracellular Ca\textsuperscript{2+} elevation in rabbit ventricular cells (Loughrey et al., 2007). The ryanodine receptor inhibitor ryanodine terminated atrial tachycardia after increasing its cycle length in a heart failure model of AF (Table 7). The anti-arrhythmic mechanism is unknown, but since this drug inhibits sarcoplasmic reticular Ca\textsuperscript{2+} release and this model produces spontaneous atrial depolarisations (Stammler et al., 2003), a suppression of non-reentrant activity is possible. Tetracaine, which also inhibits ryanodine receptors, suppressed AF in a transgenic mouse model (Table 7). An associated reduction in the incidence of spontaneous sarcoplasmic reticular Ca\textsuperscript{2+} release events in atrial cells (Sood et al., 2008) again suggests suppression of non-reentrant activity. However, an anti-reentrant contribution from I\textsubscript{Ks} blockade should not be excluded. The anti-fibrotic, pirfenidone, attenuated heart failure-induced atrial conduction-slowing in dogs, in line with an observed attenuation of fibrogenesis and associated cytokine disruption, and did not affect ERP (Table 7). It also attenuated conduction velocity-dispersion which, by reducing electrical heterogeneity, could inhibit reentry. Finally, the 5-hydroxytryptamine\textsubscript{4} antagonist RS-100302 terminated AF in a pig model. This was associated with an increase in atrial wavelength from increased ERP with minimal conduction-slowing, and with no change in ventricular ERP or QT. The increased wavelength, coupled with decreased ERP-dispersion, could inhibit reentry, the main mechanism of AF in this model. However, suppression of non-reentrant activity should not be excluded since, in human atrial isolated cells, another 5-hydroxytryptamine\textsubscript{4} antagonist, GR-113808, suppressed “cellular arrhythmic depolarisations”, which may represent abnormal automaticity or afterdepolarisations (Pau et al., 2007).

11. Concluding remarks and future directions

An overview of these data on in-vivo electrophysiological mechanisms of pharmacological termination and prevention of AF, as represented in Figure 1, allows several conclusions to be drawn. Studies of effects of class I drugs suggest that Na\textsuperscript{+} channel blockade per se can terminate AF by decreasing atrial conduction velocity and slowing spiral wave reentry. Any effect of these drugs to increase atrial ERP, including from concurrent block of K\textsuperscript{+} channels, and particularly in disease states that shorten the ERP, should contribute to AF termination by increasing wavelength. From the limited available data on effects of class II drugs in in-vivo models of AF, the mechanisms by which acute β-blockade suppresses AF are rather unclear. However, numerous in-vitro studies suggest a prominent contribution from inhibition of atrial pro-arrhythmic effects of catecholamines, likely involving a reduction in non-reentrant mechanisms by limiting excessive Ca\textsuperscript{2+} influx. This is in line with clinical effects of these drugs to suppress AF associated with elevated adrenergic tone. The chronic use of β-blockers may provide an additional, potentially anti-reentrant action, by an adaptive prolongation of the atrial ERP; so called pharmacological remodelling. Class III drugs may block I\textsubscript{Kr} only or multiple ion currents, but a general effect of inhibiting atrial reentry by increasing atrial ERP is likely their main anti-arrhythmic mechanism, in a variety of disease settings. However, a diminution or loss of class III effect of some of these drugs may occur as a result of electrical remodelling. Furthermore, many of the class III drugs risk ventricular pro-arrhythmia. Mechanistic data on the influence of class IV drugs on AF suggest that any beneficial effect of the rate-controlling Ca\textsuperscript{2+} channel blockers on atrial rhythm during AF may be lost as a result of electrical remodelling. Limited data suggest that Ca\textsuperscript{2+} channel blockers might be more effective in suppressing heart failure-induced AF, possibly by inhibiting non-reentrant mechanisms. However, these drugs cannot be used in patients with heart failure because of their ventricular negative inotropic effects. The main atrial anti-arrhythmic mechanism of most of the upstream therapies was a potentially reentry-inhibiting improvement in atrial conduction resulting from inhibition of atrial fibrosis and myocyte degradation, rather than from any substantial effects on repolarisation. Thus, in heart failure models of AF, which feature prominent atrial structural remodelling, ACE inhibitors, statins and poly-unsaturated fatty acids each decreased atrial conduction-heterogeneity. The predominant atrial anti-arrhythmic mechanism of many investigational ion channel blockers was probably suppression of leading circle reentry, by an increase in ERP and wavelength, without a decrease in conduction velocity. However, inhibition of spiral wave reentry and/or non-reentry likely contributed in some cases. Many of these drugs increased the QT interval and thus risked ventricular pro-arrhythmia. However, some were relatively atrial-, and also potentially disease-, selective, and did not prolong QT. Gap junction-enhancers tended to improve atrial conduction, but were only moderately effective in preventing AF. A multitude of actions of some investigational drugs, including atrial-predominant modulation of multiple ion channels, autonomic receptors, and intracellular Ca\textsuperscript{2+}-handling, likely contributed to their anti-AF effects in highly complex, pathology-dependent ways.

It may be noted that extensive investigation of in-vivo mechanistic electrophysiological effects of drugs in different models of AF seems not to be a requirement for their approval for the treatment of patients with AF, e.g., for the recently approved dronedarone, or the first available class III drug, amiodarone. However, as highlighted by this review, such investigations have demonstrated that the efficacy of drugs to suppress AF may be quite different in different disease states underlying the arrhythmia, and at different time points during the progression of electrical and structural remodelling. Perhaps future drug-testing may focus more on models of AF that produce marked atrial structural as well as electrical remodelling (and not necessarily primarily in dogs, e.g., see Table 7), including for ion channel blockers, i.e. non-upstream therapies. Studies of ventricular tissue have highlighted temporal heterogeneities of APD and restitution as pro-arrhythmic, particularly those resulting from alternating changes (alternans) of APD and the systolic intracellular
Ca\textsuperscript{2+} transient. Such alternans could be pro-arrhythmic in atrium also (Blatter et al., 2003), but this will require further investigation, including in-vivo. Current theories concerning the cellular mechanisms of alternans infer a pathological disruption of sarcoplasmatic reticular function; the prevention of which could provide a novel route for pharmacological intervention independent of classic ion channel blockade. The study of mechanisms of atrial-predominant, multiple-action drugs in development, as well as of currently available drugs, in in-vivo models of AF should help inform about patient groups most likely to benefit from such treatments, and potentially about appropriate timing of differing drug therapy-types during the progression of AF, as the predominating arrhythmia mechanisms change. Furthermore, as mathematical models of atrial electrophysiology incorporate increasingly realistic anatomical and functional parameters relating to the development of AF, these should also help inform about potential electro-pharmacological mechanisms of AF termination and prevention.

It is hoped that the study of electrophysiological mechanisms of acute and chronic effects of anti-arrhythmic drugs in a variety of types of in-vivo, and in-vitro, models of AF, aided by mathematical modelling, will improve our understanding of how we might increase the efficacy and safety of pharmacological treatments for preventing AF in patients.

References


Mancarella, S., Yue, Y., Karnabi, E., Qu, Y., El-Sherif, N., & Boutjdir, M. (2008). Impaired Ca\textsuperscript{2+} homeostasis is associated with atrial fibrillation in the \(a_{\text{1D}}\) L-type Ca\textsuperscript{2+} channel KO mouse. *Am J Physiol* 295, H2017-H2024.


**Acknowledgements**

British Heart Foundation for financial support (Basic Science Lectureship Award, renewal: BS/06/003)
Figure 1
Overview of in-vivo electrophysiological mechanisms of AF and their pharmacological termination or prevention. Diagram shows main reentrant and non-reentrant arrhythmia mechanisms predisposing to (constituting a “substrate” for) AF, along with the drug types which inhibit them. $\lambda$=reentry circuit wavelength; ERP=effective refractory period; $\theta$=conduction velocity; EG=excitable gap; AFCL=AF cycle length; AA=abnormal automaticity; EAD=early afterdepolarisation; DAD=delayed afterdepolarisation; TA=triggered activity; class I-IV=Vaughan Williams class of anti-arrhythmic drug; UT=upstream therapy; ID=investigational anti-arrhythmic drug; “?”=potential drug action or non-reentrant mechanism: requires confirmation in-vivo
### Table 1

**In-vivo** animal models and clinical studies of AF used, or not used* for drug investigations, showing pathology-induced changes in atrial electrophysiology

<table>
<thead>
<tr>
<th>In-vivo model /clinical study</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>λ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventricular M*</td>
<td>Dog</td>
<td>1inc/dur</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Miyachi et al. 2003</a></td>
</tr>
<tr>
<td>HF: VTP 16wk*</td>
<td>Dog</td>
<td>1dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Sridhar et al. 2009</a></td>
</tr>
<tr>
<td>HF: VTP 2-6wk</td>
<td>Sheep, dog, rabbit</td>
<td>1vul/1inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Power et al. 1998; Li et al. 1999; Shinagawa et al. 2002c; Stambler et al. 2003; Cha et al. 2004; Shroff et al. 2006; Shimano et al. 2008; Laurent et al. 2008b</a></td>
</tr>
<tr>
<td>HF: VTP+ATP</td>
<td>Dog</td>
<td>1vul/1dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Shinagawa et al. 2002a; Shinagawa et al. 2002c; Laurent et al. 2008a; Ramadeen et al. 2010</a></td>
</tr>
<tr>
<td>LVH</td>
<td>Mouse</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Zhang et al. 2006</a></td>
</tr>
<tr>
<td>Clinical HF*</td>
<td>Human</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Sanders et al. 2003</a></td>
</tr>
<tr>
<td>Acute atrial dil.</td>
<td>Human</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Chen et al. 1998</a></td>
</tr>
<tr>
<td>Acute atrial infarction*</td>
<td>Human</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Kistler et al. 2006; Lau et al. 2010</a></td>
</tr>
<tr>
<td>Local nerve-stim.</td>
<td>Dog</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Kumagai et al. 2004; Ryu et al. 2007</a></td>
</tr>
<tr>
<td>Asphyxia</td>
<td>Rat</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Haugan et al. 2004; Diness et al. 2010</a></td>
</tr>
<tr>
<td>Atrial injury</td>
<td>Dog</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Vardas, 1993</a></td>
</tr>
<tr>
<td>Acutely ischemic</td>
<td>Dog, cat</td>
<td>1inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Winslow, 1981; Hashimoto et al. 2006</a></td>
</tr>
<tr>
<td>I/I ion channel*</td>
<td>T-mouse</td>
<td>1vul/1inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Li et al. 2004; Temple et al. 2005; Zhang et al. 2005; Mancarella et al. 2008</a></td>
</tr>
<tr>
<td>Lmannin*</td>
<td>T-mouse</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Hagendorff et al. 1999</a></td>
</tr>
<tr>
<td>TROS/fibrillation*</td>
<td>T-mouse</td>
<td>1vul/1inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Sawaya et al. 2007; Reil et al. 2010</a></td>
</tr>
<tr>
<td>LMCa*1C protein</td>
<td>T-mouse</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Sood et al. 2008; Chelu et al. 2009</a></td>
</tr>
<tr>
<td>Chronic AF</td>
<td>Pig, goat</td>
<td>1vul/1dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Wijffels et al. 1995; Bauer et al. 2005; Eitsha et al. 2006; Greiser et al. 2009</a></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Sheep, dog</td>
<td>1vul/1inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Morito et al. 1995; Gaspo et al. 1997; Li et al. 1999; Fareh et al. 2001; Tang et al. 2006; Anne et al. 2007; Nakashima &amp; Kumagai, 2007; Lenaerts et al. 2009; Zhao et al. 2010</a></td>
</tr>
<tr>
<td>Clinical AF</td>
<td>Human</td>
<td>1vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="#">Kumagai et al. 1991; Fuji et al. 2001; Kim et al. 2002; Kojio et al. 2007</a></td>
</tr>
</tbody>
</table>

Arrows show reported direction of change in atrial fibrillation (AF) vulnerability (vul), incidence (inc) and duration (dur); atrial effective refractory period (ERP), conduction velocity (θ); and AF cycle length (CL), in various animal models of AF, relative to a pre-intervention control; or associated with the presence of a clinical disease; from selected representative references. MI=myocardial infarction; HF=heart failure; VTP=ventricular tachypacing; ATP=atrial tachypacing; LVH=left ventricular hypertrophy; T-mouse=transgenic mouse; ROS=reactive O2 species; Ca2+=intracellular Ca2+; Acute ATP=atrial tachypacing-induced brief (5-10min) episodes of AF in patients.
Table 2
**In-vivo** effects of class I anti-arrhythmic drugs (Na⁺ channel blockers) on AF and atrial electrophysiology in animal models or clinical studies of AF

<table>
<thead>
<tr>
<th>Drug</th>
<th>In-vivo model</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>λ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cibenzoline</td>
<td>Chronic AF</td>
<td>Goat</td>
<td>Term/vul</td>
<td>1</td>
<td>↓</td>
<td>+↓</td>
<td>+↑</td>
<td>Wijffels et al., 1999; Wijffels et al., 2000; Shan et al., 2004; Eijsbouts et al., 2006</td>
</tr>
<tr>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Brugada et al., 1993</td>
</tr>
<tr>
<td></td>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Brugada et al., 1993; Fujiki et al., 2001</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Inoue et al., 1991</td>
</tr>
<tr>
<td></td>
<td>Clinical AF</td>
<td>Human</td>
<td>ivul</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Ishibashi et al., 1995</td>
</tr>
<tr>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Brugada et al., 1993</td>
</tr>
<tr>
<td>Flecainide</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/idur</td>
<td>1</td>
<td>↓</td>
<td></td>
<td></td>
<td>Wang et al., 1992; Rivard et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>*dur</td>
<td>**</td>
<td>**</td>
<td></td>
<td></td>
<td>Rivard et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Asphyxia</td>
<td>Rat</td>
<td>idur/ivul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Haugan et al., 2004</td>
</tr>
<tr>
<td></td>
<td>Chronic AF/ATP</td>
<td>Goat, dog</td>
<td>Term/idur</td>
<td>+↑</td>
<td>+↑</td>
<td>+↑</td>
<td>+↑</td>
<td>Wijffels et al., 1999; Wijffels et al., 2000; Shinagawa et al., 2003; Duytschaever et al., 2005; Eijsbouts et al., 2006</td>
</tr>
<tr>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Briffi et al., 1999</td>
</tr>
<tr>
<td></td>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Kirchhof et al., 2005; Tuan et al., 2010</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>David et al., 1990</td>
</tr>
<tr>
<td>Moricizine</td>
<td>Pericarditis</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td>↓</td>
<td></td>
<td></td>
<td>Ortiz et al., 1994</td>
</tr>
<tr>
<td>Pilsicainide</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>Hayashi et al., 1998; Kanki et al., 1998; Shinagawa et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td>↑</td>
<td></td>
<td></td>
<td>Wang et al., 1993; Vereckei et al., 2001</td>
</tr>
<tr>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>Term/idur</td>
<td>**</td>
<td></td>
<td></td>
<td></td>
<td>Derakhchan et al., 1994; Jalil et al., 1997</td>
</tr>
<tr>
<td></td>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Fujiki et al., 2001</td>
</tr>
<tr>
<td>Propafenone</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/idur</td>
<td>1</td>
<td>↓</td>
<td></td>
<td></td>
<td>Wang et al., 1993; Niu et al., 2009</td>
</tr>
<tr>
<td></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>Inoue et al., 1991; Derakhchan et al., 1994</td>
</tr>
<tr>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>Term/idur/dur</td>
<td>**</td>
<td></td>
<td></td>
<td></td>
<td>Yu et al., 1998; Briffi et al., 1999</td>
</tr>
<tr>
<td></td>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td></td>
<td>Tai et al., 1998</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Chi et al., 1998</td>
</tr>
<tr>
<td></td>
<td>Chronic AF</td>
<td>Goat</td>
<td>Term/ivul</td>
<td>+↑</td>
<td>+↑</td>
<td>+↑</td>
<td>+↑</td>
<td>Wijffels et al., 1999; Wijffels et al., 2000</td>
</tr>
</tbody>
</table>

Term=acute termination of AF after drug administration. See legend of Table 1 for other definitions
**Table 3**

*In-vivo* effects of class II anti-arrhythmic drugs (β-blockers) on AF and atrial electrophysiology in animal models or clinical studies of AF

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class II</th>
<th>In-vivo model /clinical study</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>λ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esmolol</td>
<td></td>
<td>Local nerve-stim.</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schauerte et al., 2001</td>
</tr>
<tr>
<td>Nadolol</td>
<td></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td></td>
<td>+/dur</td>
<td></td>
<td></td>
<td></td>
<td>Rivard et al., 2007</td>
</tr>
<tr>
<td>Propranolol</td>
<td></td>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rivard et al., 2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stambler et al., 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Local nerve-stim.</td>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schauerte et al., 2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asphyxia</td>
<td>Rat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Haugan et al., 2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chronic AF</td>
<td>Goat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wijffels et al., 1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acute ATP</td>
<td>Human</td>
<td>i/inc/dur</td>
<td>**</td>
<td></td>
<td></td>
<td>Yu et al., 1998</td>
<td></td>
</tr>
</tbody>
</table>

See legend of Table 1 for definitions
Table 4  
In-vivo effects of class III (action potential-prolonging) anti-arrhythmic drugs on AF and atrial electrophysiology in animal models or clinical studies of AF

<table>
<thead>
<tr>
<th>Drug class III</th>
<th>In-vivo model /clinical study</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>λ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amodarone</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huang et al., 2006</td>
</tr>
<tr>
<td>Asphyxia</td>
<td>Rat</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Huang et al., 2004; Diness et al., 2010</td>
</tr>
<tr>
<td>Aconitine</td>
<td>Term</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Winslow, 1981</td>
</tr>
<tr>
<td>Chronic AF/ATP</td>
<td>Goat, dog Term/i/vul/ i/vul/dur</td>
<td>1/* 1/1 1</td>
<td>Shinagawa et al., 2003; Ashikaga et al., 2006; Linz et al., 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ATP</td>
<td>Human</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yuzawa et al., 1998</td>
</tr>
<tr>
<td>Clinical AF</td>
<td>Term</td>
<td></td>
<td>1</td>
<td>+/* 1</td>
<td></td>
<td>Tai et al., 1998; Pandolfo et al., 2003; Maury &amp; Zimmermann, 2004; Rostock et al., 2005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dofetilide</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>Term/i/vul/dur</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Li et al., 2000</td>
<td></td>
</tr>
<tr>
<td>Chronic atrial dil.</td>
<td>Dog Term/i/vul</td>
<td>1</td>
<td>↓</td>
<td>1</td>
<td>Restivo et al., 2001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholinergic-stim.</td>
<td>Dog Term/*ferm /i/vul/*ferm /i/vul/dur</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Nattel et al., 1998; Derakhchan et al., 2001; Rivard et al., 2007</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>*d</td>
<td></td>
<td>** 1</td>
<td></td>
<td>Rivard et al., 2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial injury</td>
<td>Term</td>
<td></td>
<td>1</td>
<td>↓ 1</td>
<td></td>
<td>Cha et al., 1996</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic AF/ATP</td>
<td>Goat, dog Term/i/vul/dur</td>
<td>/<em>1 ** 1</em></td>
<td>Li et al., 2000; Shinagawa et al., 2003; Blaauw et al., 2004; Chandra et al., 2004; Linz et al., 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibutidine</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td>Vereckei et al., 2001</td>
<td></td>
</tr>
<tr>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Stump et al., 2005</td>
<td></td>
</tr>
<tr>
<td>Chronic AF/ATP</td>
<td>Goat, dog Term/*ferm /i/vul/*ferm /i/vul/dur</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Blaauw et al., 2004; Vereckei et al., 2004; Duyschaeve et al., 2005</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ATP</td>
<td>Human</td>
<td>Term</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Sticherling et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>1</td>
<td>↓ 1</td>
<td></td>
<td>Tai et al., 1998</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nifekalant</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Hayashi et al., 1998</td>
<td></td>
</tr>
<tr>
<td>Chronic AF/ATP</td>
<td>Goat, dog Term/*ferm /i/vul/*ferm /i/vul/dur</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Tang et al., 2006</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical AF</td>
<td>Human</td>
<td>Term</td>
<td>1</td>
<td>↓ 1</td>
<td></td>
<td>Minami et al., 2004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotalol</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/*ferm/ i/vul/ i/vul</td>
<td>1</td>
<td>** 1</td>
<td></td>
<td>Wang et al., 1993; Wang et al., 1994; Derakhchan et al., 2001</td>
<td></td>
</tr>
<tr>
<td>Asphyxia</td>
<td>Rat</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Haugan et al., 2004</td>
</tr>
<tr>
<td>Chronic AF/ATP</td>
<td>Goat, dog Term/*ferm /i/vul/*ferm /i/vul/dur</td>
<td>1/* 1/1 1</td>
<td>Wijffels et al., 1999; Wijffels et al., 2000; Duyschaeve et al., 2005; Sakamoto et al., 2009</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ATP</td>
<td>Human</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yu et al., 1998</td>
</tr>
<tr>
<td>Clinical AF</td>
<td>Human</td>
<td>*vul</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Tse &amp; Lau, 2002; Kirchhof et al., 2005</td>
<td></td>
</tr>
</tbody>
</table>

See legend of Table 1 for definitions
Table 5

*In-vivo* effects of class IV anti-arrhythmic drugs (Ca$^{2+}$ channel blockers) on AF and atrial electrophysiology in animal models or clinical studies of AF

<table>
<thead>
<tr>
<th>Drug</th>
<th>In-vivo model/clinical study</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>λ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bepridil</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>Nishida et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>+inc/dur</td>
<td>↑</td>
<td></td>
<td></td>
<td>Rivard et al., 2007</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>iinc/dur</td>
<td>**</td>
<td>↑</td>
<td>**</td>
<td>Rivard et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td></td>
<td>Dog</td>
<td>+dur</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>Fareh et al., 2001</td>
<td></td>
</tr>
<tr>
<td>Efonidipine</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>↑</td>
<td>**</td>
<td>↑</td>
<td></td>
<td>Ohashi et al., 2004</td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>Term/+term/i/vul</td>
<td>↑</td>
<td></td>
<td></td>
<td>Stambler et al., 2003; Ryu et al., 2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute atrial dil.</td>
<td>Human</td>
<td>i/vul</td>
<td>↑</td>
<td></td>
<td></td>
<td>Tse et al., 2001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asphyxia</td>
<td>Rat</td>
<td>+vul/1dur</td>
<td>↓</td>
<td>**</td>
<td>↓</td>
<td>Haugan et al., 2004</td>
<td></td>
</tr>
<tr>
<td>Chronic AF</td>
<td>Goat</td>
<td>1dur</td>
<td>↓/↑</td>
<td>**</td>
<td></td>
<td></td>
<td>Duytschaever et al., 2000</td>
<td></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/+vul/dur/1dur</td>
<td>↑/**</td>
<td>**</td>
<td>↑/**</td>
<td>Lee et al., 2000; Ohashi et al., 2004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute ATP</td>
<td>Human</td>
<td>+term/i/vul/1inc/dur/1dur</td>
<td>↑</td>
<td>↓</td>
<td></td>
<td>Dacoud et al., 1997; Yu et al., 1998; Sticherling et al., 2002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See legend of Table 1 for definitions
Table 6

**In-vivo** effects of upstream therapies & other clinically-available non-Vaughan Williams class agents on AF and atrial electrophysiology in animal models of AF

<table>
<thead>
<tr>
<th>Agent</th>
<th><strong>In-vivo model</strong></th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th></th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilazapril: ACEI</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Li et al., 2007</td>
</tr>
<tr>
<td>Enalapril: ACEI</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/dur</td>
<td></td>
<td></td>
<td></td>
<td>Li et al., 2001</td>
</tr>
<tr>
<td>Candesartan: ARB</td>
<td>HF: VTP 2-6wk</td>
<td>Rabbit</td>
<td>i/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2008</td>
</tr>
<tr>
<td>Quinapril: ACEI</td>
<td>Chronic ATP</td>
<td>Sheep</td>
<td>i/inc</td>
<td></td>
<td></td>
<td></td>
<td>Shinagawa et al., 2002b</td>
</tr>
<tr>
<td>Losartan: ARB</td>
<td>Chronic ATP</td>
<td>Sheep</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td>Li et al., 2001</td>
</tr>
<tr>
<td>Olmesartan: ARB</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td><em>dur</em></td>
<td></td>
<td></td>
<td></td>
<td>Shinagawa et al., 2002b</td>
</tr>
<tr>
<td>Valvastatin: ARB</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Li et al., 2007</td>
</tr>
<tr>
<td>Eplerenone: A-A</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td>Shiroshita-Takeshita et al., 2007a</td>
</tr>
<tr>
<td>Spironolactone: A-A</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Zhao et al., 2010</td>
</tr>
<tr>
<td>Atorvastatin: statin</td>
<td>Pericarditis</td>
<td>Dog</td>
<td>i/dur</td>
<td></td>
<td></td>
<td></td>
<td>Kumagai et al., 2004</td>
</tr>
<tr>
<td>Rosuvastatin: statin</td>
<td>TROS/fibrosis</td>
<td>T-mouse</td>
<td>i/inc</td>
<td></td>
<td></td>
<td></td>
<td>Reil et al., 2010</td>
</tr>
<tr>
<td>Simvastatin: statin</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shiroshita-Takeshita et al., 2007a</td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2004</td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2004</td>
</tr>
<tr>
<td>Fenofibrate: PPAR-α</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2008</td>
</tr>
<tr>
<td>Pioglitazone: PPAR-γ</td>
<td>HF: VTP 2-6wk</td>
<td>Rabbit</td>
<td>i/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2006</td>
</tr>
<tr>
<td>Prednisone: A-I</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2006</td>
</tr>
<tr>
<td>Ibuoprofen: A-I</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td></td>
<td></td>
<td></td>
<td>Shimano et al., 2006</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/vul</td>
<td></td>
<td></td>
<td></td>
<td>Carnes et al., 2001; Shiroshita-Takeshita et al., 2004</td>
</tr>
<tr>
<td>Digoxin: glycoside</td>
<td>Chronic AF</td>
<td>Goat</td>
<td>i/vul/dur+<em>dur</em></td>
<td></td>
<td></td>
<td></td>
<td>Tielenman et al., 1999; Duyschaever et al., 2000</td>
</tr>
<tr>
<td>Acute ATP</td>
<td>Human</td>
<td>Inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sticherling et al., 2000</td>
</tr>
</tbody>
</table>

ACEI=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; A-A=aldosterone receptor antagonist; PUFA=poly-unsaturated fatty acid; PPAR=peroxisome proliferator-activated receptor; A-I=anti-inflammatory; See legend of Table 1 for other definitions
Table 7

*In-vivo* effects of investigational anti-arrhythmic drugs on AF and atrial electrophysiology in animal models of AF

<table>
<thead>
<tr>
<th>Investigational drug</th>
<th>In-vivo model</th>
<th>Species</th>
<th>AF</th>
<th>ERP</th>
<th>θ</th>
<th>CL</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPO-1: <em>Hₜᵢₜ</em></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td></td>
<td></td>
<td>Stump et al., 2005</td>
</tr>
<tr>
<td>Aminokalant: <em>Hₜᵢₜ</em></td>
<td>Chronic AF</td>
<td>Goat</td>
<td>+Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Santos et al., 2008</td>
</tr>
<tr>
<td>E-4031: <em>Hₜᵢₜ</em></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Inoue et al., 1991</td>
</tr>
<tr>
<td>KCB-328: <em>Hₜᵢₜ</em></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Rahme et al., 2001</td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Chandra et al., 2004</td>
<td></td>
</tr>
<tr>
<td>MK499: <em>Hₜᵢₜ</em></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Stump et al., 2005</td>
</tr>
<tr>
<td>Azimilide: <em>Hₜᵢₜ</em></td>
<td>Chronic atrial dil.</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Restivo et al., 2001</td>
</tr>
<tr>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Nattel et al., 1998</td>
<td></td>
</tr>
<tr>
<td>HMR 1556: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>i/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Nakashima et al., 2004</td>
</tr>
<tr>
<td>Chronic AF</td>
<td>Pig</td>
<td>Term</td>
<td></td>
<td></td>
<td></td>
<td>Bauer et al., 2005</td>
<td></td>
</tr>
<tr>
<td>NS8593: <em>Hₜᵢₜ</em></td>
<td>Asphyxia</td>
<td>Rat</td>
<td>i/dur</td>
<td></td>
<td></td>
<td>Dines et al., 2010</td>
<td></td>
</tr>
<tr>
<td>NIP-151: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Hashimoto et al., 2008</td>
</tr>
<tr>
<td>Aconitine</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Hashimoto et al., 2006</td>
<td></td>
</tr>
<tr>
<td>Tertalin: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Hashimoto et al., 2006</td>
</tr>
<tr>
<td>Cariporide: <em>Hₜᵢₜ</em></td>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Jayachandran et al., 2000</td>
<td></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Shinagawa et al., 2002</td>
<td></td>
</tr>
<tr>
<td>Ambisidine: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/Inc</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Wang et al., 1994</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>Dog</td>
<td>Inc</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Wang et al., 1994</td>
<td></td>
</tr>
<tr>
<td>AVE0116: <em>Hₜᵢₜ</em></td>
<td>Chronic AF</td>
<td>Goat</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Blauw et al., 2004; Blauw et al., 2007; Linz et al., 2007</td>
</tr>
<tr>
<td>AZD7009: <em>Hₜᵢₜ</em></td>
<td>Pericarditis</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Goldstein et al., 2004</td>
</tr>
<tr>
<td>Nilbentan: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fedorov et al., 2000</td>
</tr>
<tr>
<td>NIP-142: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Naegawa et al., 2002</td>
</tr>
<tr>
<td>Roanolazine: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Pig</td>
<td>vul/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Kumar et al., 2009</td>
</tr>
<tr>
<td>SD-3212: <em>Hₜᵢₜ</em></td>
<td>Atrial injury</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fuji et al., 2007</td>
</tr>
<tr>
<td>SSRT149744C: <em>Hₜᵢₜ</em></td>
<td>Cholinergic-stim.</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Gaulier et al., 2005</td>
</tr>
<tr>
<td>Tadasim: <em>Hₜᵢₜ</em></td>
<td>Chronic AF</td>
<td>Goats</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fischbach et al., 2001</td>
</tr>
<tr>
<td>Chronic AF</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fischbach et al., 1999</td>
<td></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fischbach et al., 2001</td>
<td></td>
</tr>
<tr>
<td>Vanoxerine: <em>Hₜᵢₜ</em></td>
<td>Pericarditis</td>
<td>Dog</td>
<td>Term</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Matsumoto et al., 2010</td>
</tr>
<tr>
<td>AAP10: <em>Hₜᵢₜ</em></td>
<td>Asphyxia</td>
<td>Rat</td>
<td><em>vul/dur</em></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Haugan et al., 2004</td>
</tr>
<tr>
<td>GAP-134: <em>Hₜᵢₜ</em></td>
<td>HF: VTP+ATP</td>
<td>Dog</td>
<td><em>vul/dur</em></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Laurent et al., 2010</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>Dog</td>
<td><em>vul/dur</em></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Rossman et al., 2009</td>
<td></td>
</tr>
<tr>
<td>Rotgaptide: <em>Hₜᵢₜ</em></td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td><em>vul/dur</em></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Shirotosha-Takeshita et al., 2007</td>
</tr>
<tr>
<td>Atrial ischaemia</td>
<td>Dog</td>
<td>i/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Shirotosha-Takeshita et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Chronic ATP</td>
<td>Dog</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Shirotosha-Takeshita et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Motolrad: <em>Hₜᵢₜ</em></td>
<td>Chronic ATP</td>
<td>Dog</td>
<td>i/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Fareh et al., 2001</td>
</tr>
<tr>
<td>K201: <em>Hₜᵢₜ</em></td>
<td>Pericarditis</td>
<td>Dog</td>
<td>i/vul/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Kumagai et al., 2003</td>
</tr>
<tr>
<td>Ryanodine: <em>RyR</em> inhibitor</td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Stambler et al., 2003</td>
</tr>
<tr>
<td>Tetracaine: <em>Hₜᵢₜ</em></td>
<td>Mouse</td>
<td>i/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Sood et al., 2008</td>
<td></td>
</tr>
<tr>
<td>Pirfenidone: <em>fibrosis</em></td>
<td>HF: VTP 2-6wk</td>
<td>Dog</td>
<td>i/dur</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Lee et al., 2006</td>
</tr>
<tr>
<td>RS-100352: 5-HT₁ antagonist</td>
<td>Atrial injury</td>
<td>Pig</td>
<td>Term/vul</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Rahme et al., 1999</td>
</tr>
</tbody>
</table>

See text for definitions of ion currents. Caᵢ=intracellular Ca²⁺; RyR=ryanodine receptor; 5-HT=5-hydroxytryptamine.
A cute risk factors for atrial fibrillation

Chronic risk factors for atrial fibrillation

Acute risk factors for atrial fibrillation

Atrial remodelling: structural and functional

Electrical heterogeneity: unidirectional conduction block, reentry
Inhibited by: UTs [ & IDs ?]

Short ERP: $\Rightarrow \lambda$, reentry
Inhibited by: class III, IDs [ & class I ?, chronic II ?]

Slow $\theta$: $\Rightarrow \lambda$, reentry
Inhibited by: UTs [ & class II ?, IDs ?]

High wave-tip curvature:
$\Rightarrow$ AFCL, reentry
Inhibited by: class I [ & IDs ?, class III ?]

Short excitable gap:
$\Rightarrow$ AFCL, reentry
Inhibited by: class I [ & class III ?]

Increased available path-length for reentry: $\Rightarrow$ reentry
Inhibited by: UTs

“Substrate” for AF

Leading-circle reentry

Spiral-wave reentry

Non-reentry

[AA?]: spontaneous activity
Inhibited by: class I ?, II ?, IV ?, IDs ?, UTs ?

[EADs?]: triggered activity
Inhibited by: class II ?, IV ?, IDs ?, UTs ?

[DADs?]: triggered activity
Inhibited by: class I ?, II ?, IV ?, IDs ?, UTs ?

Atrial fibrillation

Inhibited by: class I, & class III ?